var title_f18_15_18672="Chondroblastoma tibia";
var content_f18_15_18672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chondroblastoma of the proximal tibia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 397px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chondroblastoma (arrows) of the proximal tibia. The lesion has not crossed the physis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Daffner RH. Clinical Radiology: The Essentials, 3rd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18672=[""].join("\n");
var outline_f18_15_18672=null;
var title_f18_15_18673="Ablation sites for AVNRT";
var content_f18_15_18673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiofrequency ablation sites in Koch's triangle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 282px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of Koch's triangle which is bounded by the tricuspid ring and the tendon of Todoro. Koch's triangle can be divided into thirds: the anterior contains the compact AV node; the posterior contains the coronary sinus; and the middle or mid-septal third is between the anterior and posterior portions. The anterior third is associated with fast pathways, and the middle and posterior thirds with slow pathways. The anterior and posterior approaches to ablate the fast and slow pathways, respectively, are indicated by the position of the catheters (shown in green).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18673=[""].join("\n");
var outline_f18_15_18673=null;
var title_f18_15_18674="PXE neck";
var content_f18_15_18674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudoxanthoma elasticum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous, confluent yellow papules are present on the neck of this patient with pseudoxanthoma elasticum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18674=[""].join("\n");
var outline_f18_15_18674=null;
var title_f18_15_18675="Severe axillary intertrigo";
var content_f18_15_18675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Candidal intertrigo",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 527px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture shows severe axillary intertrigo. Erythema, skin breakdown, and satellite lesions are visible.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eva Rawlings Parker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18675=[""].join("\n");
var outline_f18_15_18675=null;
var title_f18_15_18676="Acute neuromusc weak algo";
var content_f18_15_18676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Approach to the adult with weakness in the emergency department",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 792px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACS: acute coronary syndrome; CN: cranial nerve; GBS: Guillan-Barr&eacute; syndrome; ICH: intracerebral hemorrhage; LE: lower extremities; LMN: lower motor neuron; MG: myasthenia gravis; NMJ: neuromuscular junction; UE: upper extremities; UMN: upper motor neuron.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Asimos AW. Weakness: A systematic approach to acute, non-traumatic, neurologic and neuromuscular causes. Emerg Med Pract 2002; 4:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18676=[""].join("\n");
var outline_f18_15_18676=null;
var title_f18_15_18677="Stellate cell activation";
var content_f18_15_18677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Phenotypic features of hepatic stellate cell activation during liver injury and resolution",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 408px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following liver injury, hepatic stellate cells undergo \"activation,\" which connotes a transition from quiescent vitamin A-rich cells into proliferative, fibrogenic and contractile myofibroblasts. The major phenotypic changes after activation include proliferation, contractility, fibrogenesis, matrix degradation, chemotaxis, retinoid loss, and white blood cell chemoattraction. Key mediators underlying these effects are shown. The fate of activated stellate cells during resolution of liver injury is uncertain but may include reversion to a quiescent phenotype and/or selective clearance by apoptosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott L Friedman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18677=[""].join("\n");
var outline_f18_15_18677=null;
var title_f18_15_18678="Coronavirus replication";
var content_f18_15_18678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Coronavirus replication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Steps in coronavirus replication that are potential targets for antiviral drugs and vaccines. The spike glycoprotein S is a good candidate for vaccines because neutralizing antibodies are directed against S. Blockade of the specific virus receptor on the surface of the host cell by monoclonal antibodies or other ligands can prevent virus entry. Receptor-induced conformational changes in the S protein can be blocked by peptides that inhibit membrane fusion and virus entry. The polyprotein of the replicase protein is cleaved into functional units by virus-encoded proteinases. Protease inhibitors may block replication. The polymerase functions in a unique membrane-bound complex in the cytoplasm, and the assembly and functions of this complex are potential drug targets. Viral mRNAs made by discontinuous transcription are shown in the cytoplasm with the protein that each encodes indicated at the right. The common 70 base long leader sequence on the 5' end of each mRNA is shown in red. Budding and exocytosis are processes essential to virus replication that may be targets for development of antiviral drugs.",
"    <div class=\"footnotes\">",
"     M: membrane protein required for virus budding; S: viral spike glycoprotein that has receptor binding and membrane fusion activities; E: small membrane protein that plays a role in coronavirus assembly; N: nucleocapsid phosphoprotein associated with viral RNA inside the virion.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Holmes, KV. SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 2003; 111:1605. Copyright &copy; 2003 American Society for Clinical Investigation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18678=[""].join("\n");
var outline_f18_15_18678=null;
var title_f18_15_18679="Anatomic danger zones in cutaneous surgery of the head and neck";
var content_f18_15_18679=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anatomic danger zones in cutaneous surgery of the head and neck",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/15/18679/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18679/contributors\">",
"     Shawn Allen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/15/18679/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18679/contributors\">",
"     Stanley J Miller, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/15/18679/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18679/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/15/18679/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 7, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H12456750\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will discuss how to identify the anatomical danger zones in the head and neck area to avoid injuries during cutaneous surgery. Basic dermatologic procedures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=see_link\">",
"     \"Dermatologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456757\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgeons operating in the head and neck area must have an in-depth understanding of the regional anatomy to achieve good surgical outcomes and avoid complications. The surgical risk of injury to nerves or other relevant anatomic structures should be discussed with the patient preoperatively, and informed written consent should be obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43094?source=see_link\">",
"     \"Informed consent\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are eight danger zones in the head and neck area where the motor or sensory nerves travel more superficially or nerve roots emerge from the skull foramina. Key structures to avoid during surgery include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The supraorbital and supratrochlear branches of the ophthalmic branch of the trigeminal nerve and accompanying blood vessels",
"     </li>",
"     <li>",
"      The infraorbital branches of the maxillary branch of the trigeminal nerve and the infraorbital vessels",
"     </li>",
"     <li>",
"      The mental branch of the mandibular branch of the trigeminal nerve",
"     </li>",
"     <li>",
"      The temporal (frontal) branch of the facial nerve",
"     </li>",
"     <li>",
"      The marginal mandibular branch of the facial nerve",
"     </li>",
"     <li>",
"      The buccal and zygomatic branches of the facial nerve and the parotid Stensen&rsquo;s duct",
"     </li>",
"     <li>",
"      The posterior triangle of the neck, including the great auricular, lesser occipital, spinal accessory, supraclavicular, phrenic, and suprascapular nerves",
"     </li>",
"     <li>",
"      The parotid gland",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9766775\">",
"    <span class=\"h1\">",
"     TYPES OF NERVE INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major types of nerve injury based upon the severity of nerve disruption and loss of axonal continuity: neuropraxia, axonotmesis, or neurotmesis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Each type has its own healing process, consequences, and management [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9766829\">",
"    <span class=\"h2\">",
"     Neurapraxia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurapraxia is segmental demyelination without interruption of axonal continuity. It is the most superficial type of nerve injury and may be caused by ischemia, blunt trauma, compression, or traction. Neurapraxia causes a temporary conduction block. Wallerian degeneration (degeneration of the axon and myelin sheath distal to the injury site) does not occur. Spontaneous recovery within weeks to a few months is the rule.",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9766836\">",
"    <span class=\"h2\">",
"     Axonotmesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In axonotmesis, the axon is disrupted and Wallerian degeneration occurs. Axonotmesis is commonly seen in crush and stretch injuries. Functional recovery is expected through axonal regeneration. The Schwann cells and an intact endoneurial tube play a key role in the regeneration process. Recovery is generally achieved over several months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9766843\">",
"    <span class=\"h2\">",
"     Neurotmesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurotmesis usually involves complete nerve transection, including myelin, axon, and various layers of connective tissue, with ensuing Wallerian degeneration. Spontaneous recovery is unlikely without surgical repair [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/4\">",
"     4",
"    </a>",
"    ]. The risk of synkinesis (involuntary activation of a muscle when another muscle is activated) is highest with neurotmesis because of loss of nerve conduit integrity, which normally guides accurate nerve regeneration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19454160\">",
"    <span class=\"h1\">",
"     CONSEQUENCES OF NERVE INJURY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418811522\">",
"    <span class=\"h2\">",
"     Sensory nerve injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paresthesia, dysesthesia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anesthesia may result from sensory nerve injury depending on the extent of the injury and the healing process.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paresthesia is an abnormal sensation such as tingling, pain, or burning and can be an early or late manifestation of a nerve injury.",
"     </li>",
"     <li>",
"      Dysesthesia, an abnormal unpleasant sensation, is often a late finding in sensory nerve injury as the nerves are healing and are more easily stimulated.",
"     </li>",
"     <li>",
"      Anesthesia or numbness is often an early and immediate result of nerve injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted that temporary injury to the nerve roots may occasionally occur in performing regional nerve blocks for surgical or cosmetic procedures. Nerve block of the supraorbital, infraorbital, and mental nerves targets the nerve roots at their origin from the skull. The accidental injection of anesthetics into the foramen may result in nerve compression and ischemia, with an ensuing neurapraxia. As the needle enters the foramen, the patient typically experiences a much greater pain than expected with routine numbing injections. Under these circumstances, the needle should be immediately withdrawn.",
"   </p>",
"   <p>",
"    Due to redundancy of sensory nerves, injury is often reversible, although the healing process can be stressful to the patient. It may require many months for full sensation to return. Neurapraxia secondary to nerve compression in the setting of regional nerve block usually resolves completely within weeks to months. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418811530\">",
"    <span class=\"h2\">",
"     Motor nerve injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries to motor nerves result in either partial paralysis (paresis) or total paralysis of the target muscles. This can lead to a functional compromise that can be cosmetically disfiguring and functionally challenging. Extirpation of cancers with perineural invasion may lead to nerve injury. In addition, motor nerve injuries have been reported in 0.3 to 2.6 percent of facelifts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Motor nerve injuries will have different consequences depending upon the location of the injury along the nerve. Proximal injuries will have more widespread effect than distal injuries where bifurcations of the trunks have already occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418811552\">",
"    <span class=\"h1\">",
"     DANGER ZONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eight danger zones in the head and neck area are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456764\">",
"    <span class=\"h2\">",
"     Sensory nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major sensory nerves of the face are branches of the trigeminal nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418811071\">",
"    <span class=\"h3\">",
"     Trigeminal nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical injury to the roots of the three main branches of the trigeminal nerve may cause widespread numbness of the areas they innervate (",
"    <a class=\"graphic graphic_figure graphicRef70877 \" href=\"UTD.htm?12/32/12802\">",
"     figure 1",
"    </a>",
"    ). However, this type of injury occurs rarely because of the deep location, immediate branching, and redundancy of these nerves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456773\">",
"    <span class=\"h4\">",
"     Supraorbital and supratrochlear nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first danger zone is located at the undersurface of the upper orbital rim and includes a circumferential area of approximately 1.5 cm (",
"    <a class=\"graphic graphic_picture graphicRef60544 \" href=\"UTD.htm?20/20/20801\">",
"     picture 1A",
"    </a>",
"    ). This area includes the supraorbital and supratrochlear branches of the ophthalmic branch of the trigeminal nerve.",
"   </p>",
"   <p>",
"    The zone can be identified by palpating the supraorbital notch located 2 to 3 mm superior to the supraorbital rim in the midpupillary line (approximately 2.5 cm lateral to midline) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/7\">",
"     7",
"    </a>",
"    ]. The supraorbital and supratrochlear nerve and vessels travel in a cephalic direction to supply blood and sensation to upper eyelid and mid forehead.",
"   </p>",
"   <p>",
"    The supraorbital nerve emerges from the supraorbital foramen and travels deep beneath the corrugator supercilii, then penetrates the frontalis muscle to provide sensation to the upper eyelid and mid forehead. Clinically differentiation between nerves and vessels is facilitated by the observation that nerve branches have a sinewy, white, flat appearance, whereas vessels have a more rounded tubular appearance, with arteries visibly pulsating on examination.",
"   </p>",
"   <p>",
"    The supratrochlear nerve lies approximately 1 cm medial to the supraorbital notch. It penetrates the corrugator supercilii and frontalis and provides sensation to the medial upper eyelid, forehead, and glabella.",
"   </p>",
"   <p>",
"    Injury to the supraorbital or supratrochlear nerve at this proximal location may have extensive sensory effects on the eyelid, conjunctiva, and forehead.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456780\">",
"    <span class=\"h4\">",
"     Infraorbital nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The second danger zone is located at the infraorbital foramen on the down-sloping surface of the maxillary bone, approximately 6 to 7 mm below the lower orbital rim in the midpupillary line and includes a circumferential area of approximately 1.5 cm (",
"    <a class=\"graphic graphic_picture graphicRef60544 \" href=\"UTD.htm?20/20/20801\">",
"     picture 1A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This area includes the infraorbital trunk of the maxillary branch of the trigeminal nerve and the infraorbital vessels. The infraorbital nerve and vessels emerge from the foramen and travel in a circumferential direction to supply blood and sensation to the ipsilateral lower eyelid, mid cheek, nasal sidewall, and upper lip. The main trunk of the nerve lies deep below the facial muscles and is rarely encountered in routine facial surgery.",
"   </p>",
"   <p>",
"    Damage to the nerve root in this area may cause widespread sensory deficits in the midface.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456787\">",
"    <span class=\"h4\">",
"     Mental nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third danger zone is located at the mental foramen of the mandible in the midpupillary line, and includes a circumferential area of approximately 1.5 cm (",
"    <a class=\"graphic graphic_picture graphicRef60544 \" href=\"UTD.htm?20/20/20801\">",
"     picture 1A",
"    </a>",
"    ). This area overlies the mental trunk of the mandibular branch of the trigeminal nerve.",
"   </p>",
"   <p>",
"    The zone is often identified by a slight dimple in the skin approximately 2.5 cm lateral to the midline and 1.3 cm superior to the inferior mandibular margin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/7\">",
"     7",
"    </a>",
"    ]. The mental nerve and vessels emerge from the foramen and travel in a circumferential direction to supply blood and sensation to the ipsilateral chin, mandible, and lower lip.",
"   </p>",
"   <p>",
"    Surgical injuries in this area occur infrequently because the nerve root lies at the level of the bony foramen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456794\">",
"    <span class=\"h2\">",
"     Motor nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major motor nerves of the face are branches of the facial nerve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H418811160\">",
"    <span class=\"h3\">",
"     Facial nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The facial nerve has multiple branches and redundancies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/9\">",
"     9",
"    </a>",
"    ]. Redundancy allows preservation of function and partial to full recovery in some cases of iatrogenic facial nerve injury. Some studies have shown that functional recovery of moderate to severe facial nerve paralysis is hastened and improved by functional training of facial mimic muscles alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/10\">",
"     10",
"    </a>",
"    ]. However, consultation with an experienced microsurgeon specializing in nerve repair is advised when obvious functional impairment is first noted [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456802\">",
"    <span class=\"h4\">",
"     Temporal (frontal) nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fourth danger zone involves the path of the temporal (frontal) branch of the facial nerve, from the superior aspect of the parotid gland to the lateral forehead (",
"    <a class=\"graphic graphic_picture graphicRef59570 \" href=\"UTD.htm?16/34/16931\">",
"     picture 1B",
"    </a>",
"    ). The nerve leaves the parotid parenchyma and travels toward the tail of the eyebrow to innervate the frontalis muscle. A line drawn from 0.5 cm below the tragus to approximately 1.5 cm lateral to the tail of the brow identifies the main course of the nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/11\">",
"     11",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    The nerve travels most superficially over the zygomatic arch, which is considered its most vulnerable point. However, cadaveric studies have shown that the temporal branch often has multiple rami at the zygomatic arch [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/12\">",
"     12",
"    </a>",
"    ]. This redundancy may help to avoid permanent and widespread ipsilateral forehead paralysis if one of the rami is injured during surgery.",
"   </p>",
"   <p>",
"    The temporal branch of the facial nerve is thought to travel just below the superficial musculoaponeurotic system (SMAS); however, several studies have shown that it often lies deep to the SMAS, below a separate parotid-temporal fascia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. An unproductive intraoperative search for the temporal nerve just below the SMAS during the SMAS facelift procedure provides some reassurance that the nerve is traveling in a deeper plane.",
"   </p>",
"   <p>",
"    Damage to the nerve roots deep in this area may cause motor deficits including the inability to raise the ipsilateral brow. In the author&rsquo;s experience, iatrogenic brow ptosis resulting from a distal nerve injury in the temple region is likely to resolve after several months via muscle recruitment from redundant innervations to the area and or subsequent spontaneous reinnervation. If the nerve is severed intraoperatively (eg, during, perineural tumor resection) an immediate direct brow lift may be performed to avoid brow ptosis during the recovery phase [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456809\">",
"    <span class=\"h4\">",
"     Marginal mandibular nerve",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fifth danger zone involves the path of the marginal mandibular branch of the facial nerve from the mandible to the lower face (",
"    <a class=\"graphic graphic_picture graphicRef59570 \" href=\"UTD.htm?16/34/16931\">",
"     picture 1B",
"    </a>",
"    ). The danger zone begins just anterior to the facial artery, where the nerve courses most superficially as it travels over the facial artery and vein. The marginal mandibular nerve is vulnerable at this site, because of its superficial course and the reduced thickness of the superficial musculoaponeurotic system.",
"   </p>",
"   <p>",
"    In most cases, the marginal mandibular nerve emerges from the inferior border of the parotid gland, travels along the angle and the inferior border of the mandible before arising anterior and superficial to the facial artery and vein at the anterior border of the masseter muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/16\">",
"     16",
"    </a>",
"    ]. Laterally, the nerve usually courses below the mandibular border until it reaches the facial artery, then it courses above the border as it travels medially toward the lower lip [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/17\">",
"     17",
"    </a>",
"    ]. Contrary to common belief that the marginal mandibular is a single branch, the nerve travels toward the oral commissure as one or two branches and terminates in more than two branches to innervate the target muscles of the lower lip and chin [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injury to the nerve may be more common with jowl and neck liposuction than with other procedures due to the superficial nerve location at the mandibular border. Damage to the nerve root in this area may cause paralysis of the muscles that depress the corner of the mouth (depressor anguli oris and depressor labii inferioris muscles). Blunt trauma from liposuction procedures may cause neurapraxia. In the author&rsquo;s experience, such neurapraxia resolves spontaneously in weeks to months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456824\">",
"    <span class=\"h4\">",
"     Buccal and zygomatic nerves and parotid Stensen's duct",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sixth danger zone involves the path of the buccal and zygomatic branches of the facial nerve as well as the parotid Stensen&rsquo;s duct (",
"    <a class=\"graphic graphic_picture graphicRef59570 \" href=\"UTD.htm?16/34/16931\">",
"     picture 1B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef77364 \" href=\"UTD.htm?11/23/11634\">",
"     figure 2",
"    </a>",
"    ). The nerves and duct leave the parotid parenchyma and travel medially toward the central face. The buccal branch and parotid duct travel in an imaginary line from the tragus toward the mid upper lip area; the zygomatic branch travels superiorly toward the ipsilateral medial canthus. The duct and one or several of the buccal branches of the facial nerve travel together and can be injured deep in this area. The parotid duct travels from the parotid parenchyma over the masseter muscle and dives medially through the buccinator muscle anterior to the buccal fat pad to empty just above the second maxillary molar.",
"   </p>",
"   <p>",
"    A cadaveric study of the anatomy of the buccal nerve in this danger zone revealed that, on average, the buccal nerve was found 3 cm lateral to the angle of the mouth and about 5 mm medial to the medial aspect of the masseter muscle [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/19\">",
"     19",
"    </a>",
"    ]. It was found 7 mm from the point of entrance of the parotid duct into the buccinator muscle and had an average distance of 5.5 mm from the facial artery.&nbsp;In another study, 17 of 20 cadaveric facial sides had a single buccal branch of the facial nerve, whereas 3 had two branches [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/20\">",
"     20",
"    </a>",
"    ]. In 16 of 20 sides, the nerve was inferior to the duct as it emerged from the parotid gland, whereas in the other 4 the nerve crossed the duct, usually from superior to inferior.",
"   </p>",
"   <p>",
"    Injury to the nerve roots deep in this area may cause motor deficits including the inability to tightly close the eye and an asymmetric smile. Damage to the buccal nerve will result in asymmetry as well as difficulty in chewing due to paralysis of masticatory muscles and flaccidity of the buccal mucosa. An asymmetric smile may occur with damage to the buccal or the zygomatic nerve, since both provide innervation of the lip elevator muscles; however, with more distal injuries, the redundancy between these nerves may facilitate preservation of function and appearance.",
"   </p>",
"   <p>",
"    Management of buccal nerve injuries may require direct repair",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    static suspensory procedures to restore baseline symmetry. Partial to full recovery may be expected over time. Nerve grafting or repair may be an option for better recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/21\">",
"     21",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Damage to the parotid duct in this area may lead to edema, pain, sialocele, fistula, abscess, and infection. If injury to the parotid duct is noted intraoperatively, attempt at immediate repair (distal ductal injuries) or ligation (proximal ductal injuries) should be performed by an experienced surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/22\">",
"     22",
"    </a>",
"    ]. In the event of delayed presentation, reanastomosis or grafting may be performed. If surgical repair is not feasible, parotid fistulas and sialoceles may be treated with conservative therapy, including oral antisialagogues, botulinum toxin A injections, parenteral feedings, and pressure dressings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/23-31\">",
"     23-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456831\">",
"    <span class=\"h2\">",
"     Mixed motor and sensory nerves",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456840\">",
"    <span class=\"h3\">",
"     Posterior triangle of the neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;The seventh danger zone involves the nerves located in the posterior triangle of the neck (",
"    <a class=\"graphic graphic_picture graphicRef59570 \" href=\"UTD.htm?16/34/16931\">",
"     picture 1B",
"    </a>",
"    ). Superficial surgery in this area may cause injury to the cutaneous sensory nerves of the cervical plexus, particularly the great auricular (GAN) and lesser occipital (LON) nerves (",
"    <a class=\"graphic graphic_figure graphicRef74987 \" href=\"UTD.htm?18/41/19091\">",
"     figure 3A",
"    </a>",
"    ). Deep surgery carries a risk of injury to the spinal accessory nerve (SAN), supraclavicular nerve, phrenic nerve, and suprascapular nerve (",
"    <a class=\"graphic graphic_figure graphicRef54142 \" href=\"UTD.htm?17/25/17814\">",
"     figure 3B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The posterior triangle is bordered posteriorly by the anterior aspect of the trapezius muscle, anteriorly by the posterior aspect of the sternocleidomastoid muscle (SCM), and inferiorly by the middle third of the clavicle. The posterior triangle includes the upper occipital triangle, which has similar anterior and posterior boundaries but is bordered inferiorly by the omohyoid muscle and contains the SAN and cervical plexus. One can draw a line from the external auditory meatus inferiorly 6.5 cm to locate Erb&rsquo;s point on the posterior border of the sternocleidomastoid muscle (SCM). Erb&rsquo;s point approximates the point where the four branches of the cervical plexus (GAN, LON, transverse cervical, and suprascapular nerve) exit from the posterior border of the SCM [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. The cutaneous nerves run on the superficial surface of the SCM in the investing fascia, while the SAN is found deep in this area, approximately 1 to 2 cm superior to this point [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Visualization of the superficial and deep nerves is critical when operating in the posterior triangle of the neck especially in open neck dissection procedures. Damage to the SAN may result in impaired motor function and chronic pain.",
"   </p>",
"   <p>",
"    Management of SAN injury often requires nerve repair or grafting for optimal recovery and is a challenging surgical endeavor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456847\">",
"    <span class=\"h2\">",
"     Parotid gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eighth danger zone includes the area of the parotid gland (",
"    <a class=\"graphic graphic_picture graphicRef59570 \" href=\"UTD.htm?16/34/16931\">",
"     picture 1B",
"    </a>",
"    ). The parotid gland has an inverted cone shape and is located in the preauricular area, bounded by the tragal cartilage and the ramus of the mandible posteriorly, the angle of the mandible inferiorly, the masseter muscle anteriorly, and the level of the tragus superiorly. The gland lies deep to the superficial musculoaponeurotic system and is invested by its own parotid fascia covering the surface of the gland.",
"   </p>",
"   <p>",
"    Parotid gland injury is a well-recognized complication of parotidectomy, facelift procedures, tumor resection, and penetrating trauma to the parotid gland [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18679/abstract/26,37-39\">",
"     26,37-39",
"    </a>",
"    ]. Two main types of parotid injuries occur in cutaneous surgery; damage to the parotid sheath and parenchyma or damage to the parotid duct. Iatrogenic damage to the parotid sheath and parenchyma may be unintentional or intentional, such as in superficial parotidectomies. Damage to the parotid duct may occur with extirpation of tumors and sharp trauma. Frequently, damage to the parotid gland or duct is not noticed intraoperatively and the patient presents within hours to days with signs and symptoms suggestive of parotid injury, such as pain and swelling worsened by eating or drinking, infection, sialocele,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    salivary fistula. (See",
"    <a class=\"local\" href=\"#H12456824\">",
"     'Buccal and zygomatic nerves and parotid Stensen's duct'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12456889\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgeons operating in the head and neck area must have an in depth understanding of the regional anatomy. The risk of injury to nerves or other relevant anatomic structures should be discussed with the patient preoperatively, and informed written consent should be obtained. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43094?source=see_link\">",
"       \"Informed consent\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The eight anatomic danger zones in the head and neck indicate areas where motor or sensory nerves travel more superficially, the parotid gland and duct are located, and nerve roots emerge from the skull foramina (",
"      <a class=\"graphic graphic_picture graphicRef60544 graphicRef59570 \" href=\"UTD.htm?28/62/29671\">",
"       picture 1A-B",
"      </a>",
"      ). Key structures to avoid are the branches of the trigeminal and facial nerves (",
"      <a class=\"graphic graphic_figure graphicRef70877 \" href=\"UTD.htm?12/32/12802\">",
"       figure 1",
"      </a>",
"      ), the spinal accessory nerve, the great auricular nerve (",
"      <a class=\"graphic graphic_figure graphicRef74987 graphicRef54142 \" href=\"UTD.htm?24/51/25401\">",
"       figure 3A-B",
"      </a>",
"      ), the parotid (Stensen&rsquo;s) duct, and the parotid gland (",
"      <a class=\"graphic graphic_figure graphicRef77364 \" href=\"UTD.htm?11/23/11634\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Injury to sensory nerves can cause a mixture of three different types of effects: paresthesia, dysesthesia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anesthesia. The area involved and the duration of these symptoms depend upon the extent of the injury and the healing process. (See",
"      <a class=\"local\" href=\"#H12456764\">",
"       'Sensory nerves'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injuries to motor nerves result in either partial paralysis (paresis) or total paralysis of the target muscle. This can lead to a functional compromise that can be cosmetically disfiguring and functionally challenging. (See",
"      <a class=\"local\" href=\"#H12456794\">",
"       'Motor nerves'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Allen S and Sengelmann R. Nerve Injury. In: Complications in Cutaneous Surgery, Gloster HM.  (Ed), Springer Science+Business Media, New York 2008. p.21.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/2\">",
"      Seddon HJ. A Classification of Nerve Injuries. Br Med J 1942; 2:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/3\">",
"      Seddon HJ. Three types of nerve injuries. Brain 1943; 66:238.",
"     </a>",
"    </li>",
"    <li>",
"     Sunderland, S. Nerve and Nerve Injuries, 2nd ed, E &amp; S Livingstone Ltd, Edinburgh 1968. p.31-60, 263-273.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/5\">",
"      Campbell WW. Evaluation and management of peripheral nerve injury. Clin Neurophysiol 2008; 119:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/6\">",
"      Baker DC, Conley J. Avoiding facial nerve injuries in rhytidectomy. Anatomical variations and pitfalls. Plast Reconstr Surg 1979; 64:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/7\">",
"      Gupta T. Localization of important facial foramina encountered in maxillo-facial surgery. Clin Anat 2008; 21:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/8\">",
"      Chrcanovic BR, Abreu MH, Cust&oacute;dio AL. A morphometric analysis of supraorbital and infraorbital foramina relative to surgical landmarks. Surg Radiol Anat 2011; 33:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/9\">",
"      Tzafetta K, Terzis JK. Essays on the facial nerve: Part I. Microanatomy. Plast Reconstr Surg 2010; 125:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/10\">",
"      Cai ZG, Shi XJ, Lu XG, et al. Efficacy of functional training of the facial muscles for treatment of incomplete peripheral facial nerve injury. Chin J Dent Res 2010; 13:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/11\">",
"      Pitanguy I, Ramos AS. The frontal branch of the facial nerve: the importance of its variations in face lifting. Plast Reconstr Surg 1966; 38:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/12\">",
"      Babakurban ST, Cakmak O, Kendir S, et al. Temporal branch of the facial nerve and its relationship to fascial layers. Arch Facial Plast Surg 2010; 12:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/13\">",
"      Trussler AP, Stephan P, Hatef D, et al. The frontal branch of the facial nerve across the zygomatic arch: anatomical relevance of the high-SMAS technique. Plast Reconstr Surg 2010; 125:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/14\">",
"      Agarwal CA, Mendenhall SD 3rd, Foreman KB, Owsley JQ. The course of the frontal branch of the facial nerve in relation to fascial planes: an anatomic study. Plast Reconstr Surg 2010; 125:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/15\">",
"      Costantino PD, Hiltzik DH, Moche J, Preminger A. Minimally invasive brow suspension for facial paralysis. Arch Facial Plast Surg 2003; 5:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/16\">",
"      DINGMAN RO, GRABB WC. Surgical anatomy of the mandibular ramus of the facial nerve based on the dissection of 100 facial halves. Plast Reconstr Surg Transplant Bull 1962; 29:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/17\">",
"      Batra AP, Mahajan A, Gupta K. Marginal mandibular branch of the facial nerve: An anatomical study. Indian J Plast Surg 2010; 43:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/18\">",
"      Nelson DW, Gingrass RP. Anatomy of the mandibular branches of the facial nerve. Plast Reconstr Surg 1979; 64:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/19\">",
"      Tubbs RS, Johnson PC, Loukas M, et al. Anatomical landmarks for localizing the buccal branch of the trigeminal nerve on the face. Surg Radiol Anat 2010; 32:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/20\">",
"      Pogrel MA, Schmidt B, Ammar A. The relationship of the buccal branch of the facial nerve to the parotid duct. J Oral Maxillofac Surg 1996; 54:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/21\">",
"      Humphrey CD, Kriet JD. Nerve repair and cable grafting for facial paralysis. Facial Plast Surg 2008; 24:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/22\">",
"      DeVylder J, Carlo J, Stratigos GT. Early recognition and treatment of the traumatically transected parotid duct: report of case. J Oral Surg 1978; 36:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/23\">",
"      Guntinas-Lichius O, Sittel C. Treatment of postparotidectomy salivary fistula with botulinum toxin. Ann Otol Rhinol Laryngol 2001; 110:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/24\">",
"      von Lindern JJ, Niederhagen B, Appel T, et al. New prospects in the treatment of traumatic and postoperative parotid fistulas with type A botulinum toxin. Plast Reconstr Surg 2002; 109:2443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/25\">",
"      Marchese-Ragona R, Marioni G, Restivo DA, Staffieri A. The role of botulinum toxin in postparotidectomy fistula treatment. A technical note. Am J Otolaryngol 2006; 27:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/26\">",
"      Barron R, Margulis A, Icekson M, et al. Iatrogenic parotid sialocele following rhytidectomy: diagnosis and treatment. Plast Reconstr Surg 2001; 108:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/27\">",
"      Vargas H, Galati LT, Parnes SM. A pilot study evaluating the treatment of postparotidectomy sialoceles with botulinum toxin type A. Arch Otolaryngol Head Neck Surg 2000; 126:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/28\">",
"      Witt RL. The incidence and management of siaolocele after parotidectomy. Otolaryngol Head Neck Surg 2009; 140:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/29\">",
"      Lewkowicz AA, Hasson O, Nahlieli O. Traumatic injuries to the parotid gland and duct. J Oral Maxillofac Surg 2002; 60:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/30\">",
"      Landau R, Stewart M. Conservative management of post-traumatic parotid fistulae and sialoceles: a prospective study. Br J Surg 1985; 72:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/31\">",
"      Cant PJ, Campbell JA. Management of traumatic parotid sialoceles and fistulae: a prospective study. Aust N Z J Surg 1991; 61:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/32\">",
"      Hirokawa D, Eliezri Y, Desciak E, Campanelli C. Suprascapular nerve injury during Mohs surgery and review of the surgical anatomy of the nervous structures of the supraclavicular triangle. Dermatol Surg 2010; 36:1756.",
"     </a>",
"    </li>",
"    <li>",
"     Monsen, H. Anatomy of the anterior and lateral triangles of the neck. In: Mastery of Surgery, 2nd ed, Nyhus, LM, Baker, RJ (Eds), Little, Brown and Company, Boston 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/34\">",
"      Nason RW, Abdulrauf BM, Stranc MF. The anatomy of the accessory nerve and cervical lymph node biopsy. Am J Surg 2000; 180:241.",
"     </a>",
"    </li>",
"    <li>",
"     Salasche, SJ, Bernstein, et al. Surgical Anatomy of the Skin, Appleton &amp; Lange, Norwalk, CT 1988. p.12, 116&ndash;117, 263&ndash;265.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/36\">",
"      Soo KC, Hamlyn PJ, Pegington J, Westbury G. Anatomy of the accessory nerve and its cervical contributions in the neck. Head Neck Surg 1986; 9:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/37\">",
"      Chadwick SJ, Davis WE, Templer JW. Parotid fistula: current management. South Med J 1979; 72:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/38\">",
"      Pereira KD, Smith SL, Mitchell RB. Parotid sialocele in a 10-year-old girl. Ear Nose Throat J 2007; 86:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18679/abstract/39\">",
"      Abramova L, Mann M, Hessler J, Sengelmann RD. Iatrogenic parotid sialocele after excision of malignant melanoma of the cheek. Dermatol Surg 2008; 34:1584.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13706 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18679=[""].join("\n");
var outline_f18_15_18679=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12456889\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12456750\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12456757\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9766775\">",
"      TYPES OF NERVE INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9766829\">",
"      Neurapraxia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9766836\">",
"      Axonotmesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9766843\">",
"      Neurotmesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19454160\">",
"      CONSEQUENCES OF NERVE INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H418811522\">",
"      Sensory nerve injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H418811530\">",
"      Motor nerve injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H418811552\">",
"      DANGER ZONES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12456764\">",
"      Sensory nerves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H418811071\">",
"      - Trigeminal nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12456773\">",
"      Supraorbital and supratrochlear nerves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12456780\">",
"      Infraorbital nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12456787\">",
"      Mental nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12456794\">",
"      Motor nerves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H418811160\">",
"      - Facial nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12456802\">",
"      Temporal (frontal) nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12456809\">",
"      Marginal mandibular nerve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12456824\">",
"      Buccal and zygomatic nerves and parotid Stensen's duct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12456831\">",
"      Mixed motor and sensory nerves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12456840\">",
"      - Posterior triangle of the neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12456847\">",
"      Parotid gland",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12456889\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13706\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13706|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/32/12802\" title=\"figure 1\">",
"      Cutaneous fields head neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/23/11634\" title=\"figure 2\">",
"      Cheek structure lacerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/41/19091\" title=\"figure 3A\">",
"      Cutaneous innervation from cervical plexus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/25/17814\" title=\"figure 3B\">",
"      Cervical plexus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13706|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/20/20801\" title=\"picture 1A\">",
"      Trigeminal nerve danger zones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/34/16931\" title=\"picture 1B\">",
"      Facial nerve danger zones",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/51/31543?source=related_link\">",
"      Dermatologic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/5/43094?source=related_link\">",
"      Informed consent",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_15_18680="Treatment of T cell prolymphocytic leukemia";
var content_f18_15_18680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of T cell prolymphocytic leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/15/18680/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18680/contributors\">",
"     Daniel Catovsky, MD, DSc (Med), FRCPath, FRCP, FMedSci",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18680/contributors\">",
"     Claire Dearden, MD, BSc, FRCP, FRCPath",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/15/18680/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18680/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/15/18680/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18680/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/15/18680/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3803784\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prolymphocytic leukemias (PLLs) are a group of rare neoplasms characterized by a predominance of activated lymphocytes referred to as prolymphocytes in the bone marrow and peripheral blood. PLL can be of B or T cell lineage:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T cell PLL (T-PLL) is a rare T cell neoplasm composed of lymphoid cells, typically with involvement of the peripheral blood, bone marrow, lymph nodes, and spleen. The name \"prolymphocyte\" is a misnomer, as the tumor cells in this disease are of post-thymic T cell origin. This class of neoplasms includes many cases previously classified as T cell chronic lymphocytic leukemia, a category no longer included in the current World Health Organization (WHO) classification.",
"     </li>",
"     <li>",
"      B cell PLL (B-PLL) is a very rare B cell neoplasm comprised of so-called prolymphocytes, typically with involvement of the peripheral blood, bone marrow, and spleen. The name \"prolymphocyte\" in this case is also a misnomer, as the tumor cells in this disease are mature activated B cells. By definition, these prolymphocytes comprise more than 55 percent of the cells in the blood and bone marrow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the management of T-PLL. The diagnosis of T-PLL and the diagnosis and management of B-PLL are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20358?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10102?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\", section on 'Prolymphocytic leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435582\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients with T-PLL require treatment at the time of diagnosis. Active treatment is typically reserved for patients with symptomatic disease. This is principally because:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With the possible exception of allogeneic hematopoietic cell transplantation (HCT), T-PLL cannot be cured by current treatment options.",
"     </li>",
"     <li>",
"      T-PLL is a heterogenous disease. While T-PLL is typically more aggressive than B-PLL, up to 30 percent of patients with T-PLL present with initially stable or slowly progressive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among newly diagnosed patients with asymptomatic T-PLL, we suggest observation rather than immediate treatment. Therapy is indicated for patients with the following disease-related complications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weakness, night sweats, weight loss, symptomatic lymphadenopathy, or fever",
"     </li>",
"     <li>",
"      Symptomatic anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia",
"     </li>",
"     <li>",
"      Skin infiltration, pleural effusion, or central nervous system involvement",
"     </li>",
"     <li>",
"      Progressive disease, as demonstrated by increasing lymphocytosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      rapidly enlarging lymph nodes, spleen, and liver. In contrast, transient localized lymphadenopathy, occurring in response to localized infections, is not necessarily an indication for treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H435910\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ASYMPTOMATIC PLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, immediate treatment is recommended in patients with symptomatic disease. Otherwise, a period of observation is suggested. It is very important to monitor these patients closely because, unlike patients with chronic lymphocytic leukemia, patients with T-PLL inevitably progress, sometimes with a rapid course which may be fatal. (See",
"    <a class=\"local\" href=\"#H435582\">",
"     'Indications for treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    During the observation period, we perform blood counts at monthly intervals along with a clinical examination. Of particular importance is the rate of increase in blood lymphocyte count and any evidence indicating emergence of progressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptomatic disease. A blood lymphocyte doubling time less than 8.5 months has been associated with a worse prognosis and may be considered evidence of disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/2\">",
"     2",
"    </a>",
"    ]. Some clinicians choose to offer treatment in this setting, although it is our preference not to treat based on the doubling time alone. In addition to the doubling time, the initial level of blood lymphocyte count should be considered. For example, a doubling of the white cell count from 10,000 to 20,000 per microliter in less than eight months in a patient who is free of symptoms does not have the same weight in deciding to initiate therapy as a rapid doubling of the white cell count from 75,000 to 150,000 per microliter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3804053\">",
"    <span class=\"h1\">",
"     PRETREATMENT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the initiation of active therapy for patients with symptomatic disease, patients with T-PLL should undergo a pretreatment evaluation to determine the extent of disease, patient performance status (",
"    <a class=\"graphic graphic_table graphicRef58785 graphicRef72901 \" href=\"UTD.htm?43/16/44300\">",
"     table 1A-B",
"    </a>",
"    ), and assessment of comorbidities that are likely to have an impact on treatment options.",
"   </p>",
"   <p>",
"    In addition to a history and physical examination, it is our practice to perform the following pretreatment studies in patients with T-PLL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory studies include a complete blood count with differential, chemistries with liver and renal function and electrolytes, alkaline phosphatase, lactate dehydrogenase (LDH), and serologic and polymerase chain reaction testing for human T-lymphotropic viruses, type 1.",
"     </li>",
"     <li>",
"      All patients planning to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      should undergo serology testing for cytomegalovirus (IgM and IgG), herpes simplex virus (IgM and IgG), hepatitis B (HBsAg and anti-HBc), and hepatitis C (anti-HCV).",
"     </li>",
"     <li>",
"      Unilateral bone marrow aspirate and biopsy is recommended for all patients. This sample should be sent for pathologic review, immunophenotyping, cytochemistry, and conventional cytogenetics.",
"     </li>",
"     <li>",
"      Men and women with childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      or purine analogs is unlikely to result in infertility. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"       \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A chest x-ray should be obtained to evaluate for hilar and mediastinal adenopathy. We also obtain a computed tomography (CT) of the chest, abdomen, and pelvis to evaluate the bulk of disease and screen for unusual sites of involvement (eg, liver involvement).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3804676\">",
"    <span class=\"h1\">",
"     REMISSION INDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial treatment of patients symptomatic of T-PLL consists of chemotherapy administered with the goal of attaining a complete remission (CR). T cell PLL is primarily treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    -based chemotherapy. Once a CR is attained, post-remission therapy (ie, allogeneic or autologous hematopoietic cell transplantation) is given with the goal of eradicating tumor cells that cannot be detected using standard techniques (ie, minimal residual disease). (See",
"    <a class=\"local\" href=\"#H153900505\">",
"     'Post remission therapy'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Patients with symptomatic T-PLL progress quickly without treatment and have a median overall survival measured in months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The best treatment for these patients is unclear, and patients should be encouraged to enroll in clinical trials whenever possible. Data regarding the treatment of T-PLL primarily come from retrospective analyses and small prospective trials. There have been no randomized trials in this patient population. Conventional alkylator or anthracycline-based therapies are largely ineffective.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    -based chemotherapy is the preferred initial treatment for most patients with T-PLL. The purine analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    is added for patients who fail to attain a complete remission with single agent alemtuzumab. The published experience with other purine analogs (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ) as single agents in this setting is limited to small series and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our approach is consistent with the guidelines for the management of mature T cell and NK cell neoplasms developed by the British Committee for Standards in Haematology [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/7\">",
"     7",
"    </a>",
"    ]. For most patients with T-PLL, we recommend initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    -based chemotherapy, rather than other chemotherapy combinations. For eligible patients who achieve a complete remission, we suggest consolidation with an autologous or allogeneic hematopoietic cell transplantation (HCT) rather than observation. With this approach, a majority of patients will achieve a CR and a minority achieves long-term disease-free survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69897035\">",
"    <span class=\"h2\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-CD52 antibody",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    is the initial treatment of choice for most patients with T-PLL, although it has not been approved by the US Food and Drug Agency for this indication. The manufacturer of alemtuzumab has withdrawn this product from the US market as of September 4, 2012. These actions are not related to safety concerns, but instead to prepare for the planned marketing of this drug under a different name for other conditions. After this date, alemtuzumab will remain accessible through a distribution program for the treatment of chronic lymphocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/8\">",
"     8",
"    </a>",
"    ]. Applications for use in patients with T-PLL are reviewed individually.",
"   </p>",
"   <p>",
"    The majority of cases of T-PLL strongly express the CD52 antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/9\">",
"     9",
"    </a>",
"    ]. Very rarely, CD52 has been down-regulated in relapsed cases, and this has been associated with a lack of response. Thus, tumor expression of CD52 should be confirmed before starting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    therapy.",
"   </p>",
"   <p>",
"    Retrospective and prospective studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    -based chemotherapy have reported response rates ranging from 80 to 100 percent and 50 to 76 percent in patients with previously untreated and previously treated T-PLL, respectively. Complete responses are seen in 40 to 100 percent of patients. In comparison, the overall response rate with purine analogs is less than 50 percent, with few complete remissions and remission durations of less than one year [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/5,10-12\">",
"     5,10-12",
"    </a>",
"    ]. While alemtuzumab has been considered the treatment of choice for T-PLL, responses are not durable, and additional strategies (eg, autologous or allogeneic hematopoietic cell transplantation) should be considered for the consolidation of eligible patients.",
"   </p>",
"   <p>",
"    The following is a selection of the largest studies that have evaluated single-agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    in T-PLL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective series of 76 patients, 72 of whom had failed at least one prior chemotherapeutic regimen, the overall response rate (ORR) was 51 percent (40 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/13\">",
"       13",
"      </a>",
"      ]. The median progression-free and overall survival times were 4.5 and 7.5 months, respectively. Median overall survival was 15 months for patients achieving complete response.",
"     </li>",
"     <li>",
"      A prospective study of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      in 39 patients with previously treated T-PLL reported an ORR of 76 percent (60 percent complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/14\">",
"       14",
"      </a>",
"      ]. The median progression-free and overall survival rates were 7 and 10 months, respectively. One patient remained in CR 10 years after allogeneic transplantation.",
"     </li>",
"     <li>",
"      Our initial series of 11 patients with previously untreated T-PLL, available in abstract form only, reported complete responses after intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      in all 11 patients, with seven patients alive at a median follow-up of one year [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/15\">",
"       15",
"      </a>",
"      ]. We have now treated 41 therapy-na&iuml;ve patients with T-PLL with single agent alemtuzumab, nine of whom were treated on a pilot study evaluating subcutaneous administration. This study was stopped early because of the dramatic fall in response rates associated with a switch from IV administration. IV alemtuzumab produces an ORR of over 90 percent in previously untreated patients with an 81 percent complete response rate [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/16,17\">",
"       16,17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Small prospective studies have also evaluated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    in combination with other agents. As an example, a preliminary report of 18 patients with T-PLL treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (FMC) followed by alemtuzumab reported that the overall response rate increased from 66 to 88 percent after the administration of alemtuzumab [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/18\">",
"     18",
"    </a>",
"    ]. Median progression-free and overall survivals were 10.6 and 19.2 months, respectively. The combination of alemtuzumab plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    is discussed in the following section. (See",
"    <a class=\"local\" href=\"#H153900763\">",
"     'Pentostatin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The studies that have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    in T-PLL and chronic lymphocytic leukemia (CLL) have used different administration schedules and the ideal schedule is unknown. Unlike in CLL, intravenous alemtuzumab appears to be more effective than subcutaneous alemtuzumab in T-PLL [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/17\">",
"     17",
"    </a>",
"    ]. Infusion reactions are common with the first dose of alemtuzumab so it is common to premedicate with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    and gradually increase the administered dose over a few days as tolerated until reaching the standard dose. We administer alemtuzumab 3 mg intravenously on day 1; 10 mg on day 2; and 30 mg on day 3, followed by 30 mg doses every Monday, Wednesday, and Friday beginning the following week until maximum response [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/13\">",
"     13",
"    </a>",
"    ]. The prevention and management of infusion reactions is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=see_link&amp;anchor=H40#H40\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\", section on 'Alemtuzumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    increases the vulnerability of patients to opportunistic infections, including fatal bacterial, viral, fungal, and protozoal infection, as well as reactivation of cytomegalovirus (CMV), indicating that appropriate antibacterial and antiviral prophylaxis must be instituted when this agent is employed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/12,19-27\">",
"     12,19-27",
"    </a>",
"    ]. The most commonly reported prophylaxis regimens include antibiotics (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    DS or cotrimoxazole) together with antiviral agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    ) during therapy and until CD4+ cell counts are",
"    <span class=\"nowrap\">",
"     &ge;200/microL,",
"    </span>",
"    and for a minimum of two months after last treatment. CMV viremia should be measured by quantitative PCR weekly during treatment. The approach to CMV management varies by center. Some use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    prophylaxis if viremia is present, while others use it only if the viral load is rising [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/27\">",
"     27",
"    </a>",
"    ]. Our typical practice is to monitor patients as above. If a patient converts from CMV negative to CMV positive status or if a patient previously positive for CMV has an increase in viral load, we suspend therapy with alemtuzumab and begin treatment of CMV. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link&amp;anchor=H28#H28\">",
"     \"Secondary immune deficiency induced by drugs and biologics\", section on 'Alemtuzumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H153900763\">",
"    <span class=\"h2\">",
"     Pentostatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     Pentostatin",
"    </a>",
"    is the purine analog that has demonstrated the greatest activity in T-PLL. Pentostatin has been evaluated in retrospective and small prospective trials both as a single agent and in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    . Although the two drugs have not been directly compared in a randomized trial, single agent pentostatin appears to have a lower response rate than single agent alemtuzumab. For patients who fail to attain a complete remission with single agent alemtuzumab, we suggest the addition of pentostatin.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of single agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"       pentostatin",
"      </a>",
"      reported data from 55 patients with previously treated or previously untreated T-PLL [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/10\">",
"       10",
"      </a>",
"      ]. The overall response rate was 45 percent (9 percent complete) and did not vary depending upon prior therapy. Responses were seen after three to four injections. The median progression-free and overall survivals were six and nine months, respectively. Toxicities included mild to moderate nausea in approximately one-third of patients. Thrombocytopenia, neutropenia, and lymphopenia were seen in 35, 20, and 18 percent of patients, respectively. Infections were seen in approximately one-quarter of patients.",
"     </li>",
"     <li>",
"      A phase II study evaluated the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"       pentostatin",
"      </a>",
"      in 24 patients with T cell leukemia or lymphoma, 13 with T-PLL [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/28\">",
"       28",
"      </a>",
"      ]. The overall response rate in this subgroup was 69 percent (62 percent complete). For patients with T-PLL, the median overall and progression-free survivals were 10.2 and 7.8 months, respectively. Prophylactic antimicrobials with antiviral agents, antifungal agents, and anti-Pneumocystis jiroveci (previously Pneumocystis carinii) agents were mandatory during treatment and for a minimum of two months after the completion of treatment. Despite this, the most common toxicities were infection (75 percent), thrombocytopenia (37 percent), neutropenia (45 percent), and anemia (8 percent). CMV reactivation was seen in 38 percent of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    increases toxicity, but it is unclear whether it increases the response rate since there have been no randomized trials comparing combination therapy with single-agent therapy. As such, we reserve the use of pentostatin for those patients who fail to attain a complete remission after treatment with single-agent alemtuzumab. For such patients, we continue the alemtuzumab therapy three times a week and add pentostatin 4",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly. Patients who attain a complete remission with this approach can proceed to post-remission therapy. Those who do not attain a complete remission should be referred for clinical trials. (See",
"    <a class=\"local\" href=\"#H153900505\">",
"     'Post remission therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H69897308\">",
"     'Clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H153900289\">",
"    <span class=\"h1\">",
"     RESPONSE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two months following the completion of initial therapy, the response to treatment should be evaluated by history, physical examination, complete blood count with differential, bone marrow biopsy, and computed tomography (CT) of the chest, abdomen, and pelvis. The history should include questions regarding constitutional symptoms such as unintentional weight loss, fatigue, fevers, and night sweats. The physical examination should pay particular attention to the evaluation for skin lesions, lymphadenopathy, hepatomegaly, and splenomegaly. A lymph node biopsy should be obtained if transformation into an aggressive lymphoma is suspected. While patients with T-PLL do not undergo Richter transformation, they can develop an Epstein-Barr virus (EBV) driven lymphoma (similar to post-transplant lymphoproliferative disease) after treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Response is defined using criteria initially created for patients with chronic lymphocytic leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/29\">",
"     29",
"    </a>",
"    ]. A complete remission requires",
"    <strong>",
"     all",
"    </strong>",
"    of the following to be present at least two months after completion of therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Absence of constitutional symptoms attributable to T-PLL; there should be no unintentional weight loss (&ge;10 percent of body weight), fatigue that interferes with work or usual activities, fevers greater than 100.5&deg;F (&gt;38&deg;C) for &ge;2 weeks, or night sweats for &gt;1 month.",
"     </li>",
"     <li>",
"      No lymph nodes &gt;1.5 cm in diameter on CT",
"     </li>",
"     <li>",
"      No hepatomegaly or splenomegaly by CT",
"     </li>",
"     <li>",
"      Absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &gt;1500/microL",
"      </span>",
"      [1.5 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L]",
"      </span>",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &gt;100,000/microL",
"      </span>",
"      [100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L]",
"      </span>",
"     </li>",
"     <li>",
"      Untransfused hemoglobin concentration &gt;11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (110",
"      <span class=\"nowrap\">",
"       g/L)",
"      </span>",
"     </li>",
"     <li>",
"      No clonal lymphocytes in the peripheral blood by immunophenotyping",
"     </li>",
"     <li>",
"      A unilateral bone marrow aspirate and biopsy performed at least two months after the completion of therapy and before six months have elapsed is required to confirm the CR by demonstrating no disease. If a hypocellular marrow is found, the bone marrow aspirate and biopsy should be repeated in four to six weeks provided the peripheral blood counts have recovered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of a CR, a partial response (PR) is achieved when there is a &ge;50 percent reduction in detectable disease. Progressive disease is defined by a &ge;50 percent increase in detectable disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H153900505\">",
"    <span class=\"h1\">",
"     POST REMISSION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 80 percent of patients with T-PLL who undergo initial treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    will attain a complete remission (CR). However, without additional cytotoxic therapy, virtually all patients with T-PLL will relapse within one to two years. In contrast, patients who attain a CR and proceed with an allogeneic or autologous hematopoietic cell transplantation (HCT) may expect two- and five-year survival rates as high as 60 and 30 percent, respectively. For eligible patients who achieve a CR, we suggest consolidation with HCT rather than observation. Allogeneic and autologous HCT appear to produce similar survival rates, but differ in treatment-related mortality and relapse rates. In general, we prefer allogeneic HCT for younger adults with a good performance status. An autologous HCT may be considered for patients who achieve a CR but are not candidates for an allogeneic HCT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter retrospective study evaluated the outcomes of patients with T-PLL who underwent either autologous (15 patients) or allogeneic (13 patients) HCT following the attainment of a good partial response (three patients) or CR with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      , and compared these patients with 23 patients with T-PLL who achieved a CR and survived at least six months after alemtuzumab treatment but did not proceed with HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/30\">",
"       30",
"      </a>",
"      ]. When compared with allogeneic HCT, autologous HCT had a lower treatment-related mortality rate (7 versus 31 percent), but higher relapse rate (60 versus 33 percent) resulting in a similar median overall survival (52 versus 33 months). When compared with the patients who did not receive HCT, those who received autologous or allogeneic HCT appeared to have a longer median overall survival (48 versus 20 months), although a statistical comparison was not performed.",
"     </li>",
"     <li>",
"      Another retrospective analysis evaluated 47 patients with PLL (21 with T-PLL) who underwent allogeneic HCT in CR (36 percent), partial remission (18 percent), or with refractory disease (46 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/31\">",
"       31",
"      </a>",
"      ]. With a median follow-up of 13 months, the cumulative incidence of treatment-related mortality at one year was 28 percent and the one-year incidence of relapse or progression was 39 percent. The median progression-free survival for the patients with T-PLL was 5.1 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with all reports of new treatments, attention must be given to the possibility that patients receiving these treatments represent only a small, unrepresentative subset of patients with T-PLL. High intensity chemotherapy followed by allogeneic HCT in T-PLL has been limited by donor availability and the advanced age of most patients with this disorder. Following improvements in technique and supportive care and the introduction of reduced intensity conditioning regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/32\">",
"     32",
"    </a>",
"    ], the upper age limit for allogeneic HCT has been increased to 70 years. In addition, it seems likely that results with matched unrelated donor transplants are similar to those seen with matched sibling transplants, further extending the applicability of allogeneic HCT in T-PLL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=see_link&amp;anchor=H13#H13\">",
"     \"Donor selection for hematopoietic cell transplantation\", section on 'Matched unrelated donors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3804573\">",
"    <span class=\"h1\">",
"     PATIENT FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of therapy, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. The frequency and extent of these visits depend upon the comfort of both the patient and physician and the type of post-remission therapy administered. There have been no prospective, randomized trials comparing various schedules of follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=see_link\">",
"     \"Supportive care after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relapsed disease usually presents with evidence of circulating tumor cells in the blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    skin changes. It is recommended that relapsed disease suggested by changes on imaging or physical examination be confirmed by biopsy. As such, a biopsy is recommended to document relapsed disease before proceeding to salvage therapy.",
"   </p>",
"   <p>",
"    Patients with T-PLL treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematopoietic cell transplantation are immunocompromised and are therefore at risk for potentially lethal opportunistic infections with organisms such as Pneumocystis jirovecii (previously Pneumocystis carinii) and cytomegalovirus. While prophylaxis for such infections is generally given, clinicians need to consider these organisms when patients become unwell. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link\">",
"     \"Diagnosis of cytomegalovirus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69897253\">",
"    <span class=\"h1\">",
"     TREATMENT OF RELAPSED PLL",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little information on the treatment of recurrent or refractory T-PLL and patients should be referred for enrollment in clinical trials.",
"   </p>",
"   <p>",
"    Repeat treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    may have activity in patients with T-PLL. A prospective study of alemtuzumab in 38 patients with relapsed or refractory T-PLL reported a second response in 5 of 12 patients treated with alemtuzumab at relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18680/abstract/14\">",
"     14",
"    </a>",
"    ]. However, some cases of T-PLL lose CD52 expression at the time of relapse resulting in resistance to alemtuzumab. As such, CD52 expression should be reassessed by immunophenotype prior to retreatment with alemtuzumab.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69897308\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3804698\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prolymphocytic leukemias (PLLs) are a group of rare neoplasms characterized by a predominance of activated lymphocytes referred to as prolymphocytes in the bone marrow. PLL can be of B or T cell lineage. (See",
"      <a class=\"local\" href=\"#H3803784\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among newly diagnosed patients with asymptomatic T cell PLL, we suggest close observation rather than immediate treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H435582\">",
"       'Indications for treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H435910\">",
"       'Management of asymptomatic PLL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to the initiation of active therapy for patients with symptomatic disease, patients with T-PLL should undergo a pretreatment evaluation to determine the extent of disease, patient performance status, and assessment of comorbidities that are likely to have an impact on treatment options. (See",
"      <a class=\"local\" href=\"#H3804053\">",
"       'Pretreatment evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients with T cell PLL, we recommend initial treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      -based chemotherapy rather than with other chemotherapy combinations (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients who fail to attain a complete remission with single agent alemtuzumab, we suggest the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"       pentostatin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3804676\">",
"       'Remission induction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For eligible patients with T cell PLL who achieve a complete remission, we suggest consolidation with hematopoietic cell transplantation (HCT) rather than observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Allogeneic and autologous HCT appear to produce similar survival rates, but differ in treatment-related mortality and relapse rates. In general, we prefer allogeneic HCT for younger adults with a good performance status. An autologous HCT may be considered for patients who achieve a CR, but are not candidates for an allogeneic HCT. &nbsp;(See",
"      <a class=\"local\" href=\"#H153900505\">",
"       'Post remission therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is little information on the treatment of recurrent or refractory T cell PLL and patients should be referred for enrollment in clinical trials. (See",
"      <a class=\"local\" href=\"#H69897308\">",
"       'Clinical trials'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H69897253\">",
"       'Treatment of relapsed PLL'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/1\">",
"      Garand R, Goasguen J, Brizard A, et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Fran&ccedil;ais d'H&eacute;matologie Cellulaire. Br J Haematol 1998; 103:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/2\">",
"      Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood 2008; 111:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/3\">",
"      Bartlett NL, Longo DL. T-small lymphocyte disorders. Semin Hematol 1999; 36:164.",
"     </a>",
"    </li>",
"    <li>",
"     Catovsky D, Muller-Hermelink HK, Ralfkiaer E. T-cell prolymphocytic leukemia. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th, Swerdlow SH, Campo E, Harris NL, et al.  (Eds), International Agency for Research on Cancer, Lyon 2008. p.270.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/5\">",
"      Kantarjian HM, Childs C, O'Brien S, et al. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am J Med 1991; 90:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/6\">",
"      Lorand-Metze I, Oliveira GB, Aranha FJ. Treatment of prolymphocytic leukemia with cladribine. Ann Hematol 1998; 76:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/7\">",
"      Dearden CE, Johnson R, Pettengell R, et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br J Haematol 2011; 153:451.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.campath.com/index.html (Accessed on September 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/9\">",
"      Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998; 22:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/10\">",
"      Mercieca J, Matutes E, Dearden C, et al. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 1994; 12:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/11\">",
"      Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997; 15:2667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/12\">",
"      Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003; 98:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/13\">",
"      Keating MJ, Cazin B, Coutr&eacute; S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol 2002; 20:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/14\">",
"      Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001; 98:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/15\">",
"      Dearden C, Matutes E, Cazin B. Very high response rates in previously untreated T-cell prolymphocytic leukemia patients receiving alemtuzumab (Campath-1H) therapy (abstract 2378). Blood 2003; 102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/16\">",
"      Dearden C. How I treat prolymphocytic leukemia. Blood 2012; 120:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/17\">",
"      Dearden CE, Khot A, Else M, et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood 2011; 118:5799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/18\">",
"      Hopfinger G, Raoymonde B, Eichhorst B, et al. TPLL-1 protocol of the German CLL study group - A prospective phase II trial of fludarabine phosphate, mitoxantrone and cyclophosphamide (FMC) followed by alemtuzumab consolidation in T-PLL (abstract 2039). Blood 2007; 118:607a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/19\">",
"      O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003; 98:2657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/20\">",
"      Fiegl M, Falkner A, Hopfinger G, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 2006; 107:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/21\">",
"      Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005; 23:7024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/22\">",
"      Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003; 101:3413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/23\">",
"      Yang H, Rosove MH, Figlin RA. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Hematol 1999; 62:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/24\">",
"      Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol 2006; 132:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/25\">",
"      Keating M, Coutr&eacute; S, Rai K, et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 2004; 4:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/26\">",
"      Rezvany MR, Tehrani MJ, Karlsson C, et al. Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 2006; 135:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/27\">",
"      O'Brien S, Ravandi F, Riehl T, et al. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 2008; 111:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/28\">",
"      Ravandi F, Aribi A, O'Brien S, et al. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 2009; 27:5425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/29\">",
"      Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111:5446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/30\">",
"      Krishnan B, Else M, Tjonnfjord GE, et al. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol 2010; 149:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/31\">",
"      Kalaycio ME, Kukreja M, Woolfrey AE, et al. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant 2010; 16:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18680/abstract/32\">",
"      Shea T, Johnson J, Westervelt P, et al. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant 2011; 17:1395.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13937 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18680=[""].join("\n");
var outline_f18_15_18680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3804698\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3803784\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H435582\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H435910\">",
"      MANAGEMENT OF ASYMPTOMATIC PLL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3804053\">",
"      PRETREATMENT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3804676\">",
"      REMISSION INDUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69897035\">",
"      Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H153900763\">",
"      Pentostatin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H153900289\">",
"      RESPONSE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H153900505\">",
"      POST REMISSION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3804573\">",
"      PATIENT FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69897253\">",
"      TREATMENT OF RELAPSED PLL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H69897308\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3804698\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/13937\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/13937|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 1A\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 1B\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20358?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of B cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10102?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of T cell prolymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/38/26218?source=related_link\">",
"      Donor selection for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22665?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=related_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29306?source=related_link\">",
"      Supportive care after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_15_18681="Oral rehydration therapy";
var content_f18_15_18681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oral rehydration therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/15/18681/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18681/contributors\">",
"     Bonita Stanton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18681/contributors\">",
"     Joshua B Evans, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18681/contributors\">",
"     Bobby Batra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/15/18681/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18681/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18681/contributors\">",
"     Anne M Stack, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/15/18681/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18681/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/15/18681/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrheal disease is one of the leading causes of worldwide childhood morbidity and mortality, resulting in 1.4 to 2.5 million deaths annually [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Loss of intestinal fluid caused by gastroenteritis may lead to severe hypovolemia, shock, and death, particularly in children younger than five years of age.",
"   </p>",
"   <p>",
"    Although the total number of deaths globally from diarrheal diseases remains high, the overall mortality rate has steadily declined over the last few decades [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/1\">",
"     1",
"    </a>",
"    ]. This decline, especially in developing countries, is largely due to the use of early and appropriate oral rehydration therapy (ORT), as well as improved nutrition and water sanitation measures [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, diarrhea caused by gastroenteritis remains the major cause of hospitalizations",
"    <span class=\"nowrap\">",
"     (&gt;200,000/year)",
"    </span>",
"    and outpatient visits (&gt;1.5",
"    <span class=\"nowrap\">",
"     million/year);",
"    </span>",
"    this results in 300 deaths every year [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/5\">",
"     5",
"    </a>",
"    ]. The annual direct medical costs are estimated to be more than 1 billion US dollars per year.",
"   </p>",
"   <p>",
"    The early use of ORT at home in children with diarrhea decreases the number of outpatient visits and hospitalizations, and overall medical costs [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/6\">",
"     6",
"    </a>",
"    ]. Despite the success of ORT in developing countries, and established guidelines supporting its use in children with gastroenteritis by the American Academy of Pediatrics (AAP) and the Centers for Disease Control (CDC), the full benefit of ORT in the United States and other developed countries has not been realized on account of underutilization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The scientific basis and clinical application of ORT in patients with diarrhea, the composition of oral rehydration solutions (ORS), and the limitations and barriers to this therapy are discussed in this topic review. The assessment and treatment of hypovolemia in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The terms volume depletion (hypovolemia) and dehydration often are used interchangeably. However, these terms differentiate physiologic conditions resulting from different types of fluid loss. Much of the clinical literature does not differentiate between the two terms and uses them interchangeably. Thus, we will follow this convention and use the terms hypovolemia, volume depletion, and dehydration interchangeably as referring to all types of fluid deficits. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the use of oral solutions had been noted in ancient Hindu texts, the successful use of ORT was first documented in 1945 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/10\">",
"     10",
"    </a>",
"    ]. During this same period of time, intravenous hydration became readily available and was successful in treating patients with cholera [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The oral replacement solution introduced in 1945 was very similar to some of the current formulations. However, in the 1950s, commercially available ORS with inappropriately high carbohydrate levels resulted in multiple cases of hypernatremia, leading to abandonment of the use of ORS in favor of intravenous hydration to treat hypovolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The success of intravenous hydration in decreasing mortality and morbidity in children with diarrhea in developing countries led to renewed efforts in the 1960s to develop an effective ORT that would be less expensive and easier to administer. Both basic science and clinical research were directed toward understanding the pathophysiology of diarrhea and to successfully developing and implementing ORT [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHYSIOLOGIC BASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intestine has a remarkable capacity to secrete and absorb water. In normal adults, more than 6500 mL per day of fluids, including both ingested liquids and intestinal secretions, are presented to the intestinal tract and reduced to a formed stool output of less than 100",
"    <span class=\"nowrap\">",
"     mL/day.",
"    </span>",
"    This water absorption is passive depending upon the osmotic gradient that is dictated by sodium transport via the following three principal mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Na/H",
"      </span>",
"      exchangers",
"     </li>",
"     <li>",
"      Electrochemical gradient",
"     </li>",
"     <li>",
"      Sodium-coupled transport with carrier organic solutes (eg, glucose)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15188?source=see_link\">",
"     \"Pathogenesis of acute diarrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In diarrheal diseases, disruption of many of these processes occurs; however, the sodium-coupled co-transport with glucose and other carrier organic solutes remains intact, even with viral enteritis associated with epithelial damage [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The preservation of this facilitated co-transport of glucose and sodium is the basis of ORT.",
"   </p>",
"   <p>",
"    In studies from the 1960s, an ORS that was isotonic with equimolar concentrations of glucose and sodium was as effective as intravenous hydration in successfully treating patients with cholera in India and Bangladesh [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Subsequent formulations were based on these studies (",
"    <a class=\"graphic graphic_table graphicRef67494 \" href=\"UTD.htm?5/30/5613\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The desired properties for ORS as recommended by the World Health Organization (WHO) and UNICEF for global use include [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total osmolality between 200 to 310",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"     </li>",
"     <li>",
"      Equimolar concentrations of glucose and sodium",
"     </li>",
"     <li>",
"      Glucose concentration not in excess of 20",
"      <span class=\"nowrap\">",
"       g/L",
"      </span>",
"      (111",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Sodium concentration between 60 to 90",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Potassium concentration between 15 to 25",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Citrate concentration between 8 to 12",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"     </li>",
"     <li>",
"      Chloride concentration between 50 to 80",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other nonphysiologic fluids with high sugar content (eg, fruit juices and soda beverages) with a molar ratio of glucose in excess of sodium will increase diarrheal losses. The higher unabsorbed glucose load will increase the osmolality in the lumen, decreasing water absorption. Other fluids with excess sodium concentration compared with glucose (eg, chicken broth) also will increase diarrheal losses, as there is no organic solute for facilitated transport of sodium. Fluids with high sodium concentration also may result in hypernatremia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ORT has had a major beneficial impact on childhood mortality of diarrheal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/4,17\">",
"     4,17",
"    </a>",
"    ]. The number of deaths attributable to diarrhea in children younger than five years of age fell from 4.6 to 1.5 million per year from 1980 to 2000 concomitant with the increased use of ORT. Other alternative explanations for the decreased mortality appear to be less likely as confirmed by case studies in Brazil, Egypt, Mexico, and the Philippines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ORT appears to be as effective as intravenous hydration, in terms of complications and cost [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. This was shown in two meta-analysis of randomized controlled studies published in 2004 that compared ORT to intravenous therapy (IVT) in children younger than 15 years of age with gastroenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first analysis was based upon 16 trials from 1988 to 2003 and involved 1545 children in 11 countries, with one-half of the trials in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/23\">",
"     23",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Across all 16 trials, the overall failure rate of ORT was low (4 percent).",
"     </li>",
"     <li>",
"      In three trials in developed countries, there was a significantly reduced hospital stay of 21 hours in children treated with ORT as compared to IVT.",
"     </li>",
"     <li>",
"      In the five trials that provided data for major adverse events (defined as seizures or death), there was a significant increase in major adverse events in children who received IVT. However, this finding resulted largely from an excess number of events reported in only one large study. By comparison, there was no difference in the incidence of either seizures or deaths among trials only conducted in developed countries.",
"     </li>",
"     <li>",
"      IVT was more expensive, as reported in three American trials.",
"     </li>",
"     <li>",
"      There was no difference in the frequency of stools, duration of diarrhea, or weight gain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A second meta-analysis included 18 studies from 1982 to 2005 involving 1811 patients, with one-half of the trials in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/24\">",
"     24",
"    </a>",
"    ]. Results were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall, there were more treatment failures with ORT with a 4 percent relative difference (RD), 95% CI 2 to 6. This difference resulted in one failure for every 25 patients treated with ORT compared to IVT (Numbers needed to treat: 25 patients, 95% CI 17 to 50). In studies that used a lower-osmolality ORT, RD decreased to 1 percent with NNT of 100.",
"     </li>",
"     <li>",
"      There was no difference in weight gain, duration of diarrhea, risk of either hyponatremia or hypernatremia, or total fluid intake.",
"     </li>",
"     <li>",
"      In six trials, there was a reduced hospital stay with ORT.",
"     </li>",
"     <li>",
"      Phlebitis occurred more frequently in the IVT group and paralytic ileus in the ORT group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2010 systematic review including 157 manuscripts estimated that ORS is effective in preventing death due to diarrhea in 93 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/25\">",
"     25",
"    </a>",
"    ]. There was insufficient evidence to estimate the effectiveness of recommended home fluids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;ORT is recommended by the AAP, the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHN), and the European Society for Paediatric Infectious Disease (ESPID) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. It is the preferred or first-line treatment of fluid and electrolyte losses caused by diarrhea in children with mild to moderate dehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/7,26\">",
"     7,26",
"    </a>",
"    ]. This therapy is used to treat diarrhea independent of age, causative agent, or initial sodium values [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/27\">",
"     27",
"    </a>",
"    ]. Advantages of ORT include lower cost, elimination of the need for IV line placement, and treatment that can be done or continued at home.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Home",
"    </span>",
"    &nbsp;&mdash;&nbsp;If care providers are properly instructed to recognize the appropriate clinical settings, ORT can be given at home, leading to fewer outpatient and emergency department visits [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/6\">",
"     6",
"    </a>",
"    ]. Families with young children and infants should be encouraged to have a supply of ORS in the home so that they will be able to start ORT as soon as diarrhea begins.",
"   </p>",
"   <p>",
"    A standard commercial ORS is recommended for use at home (including prepackaged solutions), as major errors can occur if a homemade solution using sugar and sodium is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/28\">",
"     28",
"    </a>",
"    ]. Care providers need to recognize signs of illness or treatment failure requiring medical attention [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/9\">",
"     9",
"    </a>",
"    ]. Assessment of the patient at home with gastroenteritis is discussed elsewhere in the program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9912?source=see_link\">",
"     \"Prevention and treatment of viral gastroenteritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Medical setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to initiation of ORT, the child who presents to either the office or the emergency department with diarrhea should be evaluated to determine the underlying etiology of diarrhea and whether further diagnostic testing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intervention is necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=see_link\">",
"     \"Evaluation of diarrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     ORT based on degree of dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the decision is made to begin hydration therapy, clinical assessment of the patient's hydration status is necessary, as it guides clinical decisions in the use of ORT (",
"    <a class=\"graphic graphic_table graphicRef76198 \" href=\"UTD.htm?13/5/13404\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\", section on 'Degree of dehydration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following recommendations are based on guidelines from the AAP, CDC, WHO, ESPGHN, and ESPID [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/7,9,26,29\">",
"     7,9,26,29",
"    </a>",
"    ]. For each degree of dehydration, treatment is divided into two phases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rehydration phase &ndash; The fluid deficit is replaced quickly over three to four hours, returning the patient to a euvolemic state. ORS is administered in frequent, small amounts of fluid by spoon or syringe. A nasogastric tube can be used in the child who refuses to drink [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/7,9,30-32\">",
"       7,9,30-32",
"      </a>",
"      ]. Each aliquot given must be small enough to avoid accumulation of a large amount of fluid in the stomach that might trigger vomiting. Five mL, administered every one to two minutes, allows 150 to 300",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      to be given [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/7\">",
"       7",
"      </a>",
"      ]. If the patient is breast-fed, breastfeeding continues during this phase as well as the maintenance phase.",
"     </li>",
"     <li>",
"      Maintenance phase &ndash; Maintenance calories and fluids are administered. Rapid realimentation begins after completion of the rehydration phase, with the goal to return the patient to an age-appropriate unrestricted diet. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"       \"Maintenance fluid therapy in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During both phases, ongoing losses from diarrhea and vomiting are replaced with ORS. If the losses can be measured accurately, 1 mL of ORS should be administered for each gram of diarrheal stool. Alternatively, 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of body weight of ORS should be administered for each watery or loose stool, and 2",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of body weight for each episode of emesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     No dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with diarrhea but no evidence of dehydration, ORT is used to maintain hydration by replacement of stool losses, as previously outlined. If the stool output is modest, ORS may not be required and continued age-appropriate feeding (including breast feeding) and supplemental fluids may be sufficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Mild dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild dehydration is defined as 3 to 5 percent volume loss.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repletion phase &ndash; Hydration should be restored by administering ORT at a volume of 50",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      or five teaspoons per pound (",
"      <a class=\"graphic graphic_table graphicRef53876 \" href=\"UTD.htm?37/4/37963\">",
"       table 3",
"      </a>",
"      ). over four hours. Additional ORS is given to replace ongoing loss of stool, as previously outlined. Reassessment of the patient's hydration status and replacement of ongoing losses should occur at least every two hours.",
"     </li>",
"     <li>",
"      Maintenance phase &ndash; Once repletion is completed, feeding and fluids should be started as above. ORT is continued for ongoing diarrheal losses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Moderate dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate dehydration is defined as 6 to 9 percent volume loss. Care of patients with this degree of dehydration is best suited in a medically supervised setting such as the physician's office, the emergency department, or urgent care facility.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repletion phase &ndash; Hydration should be restored by administering ORT at a volume of 100",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      or 10 teaspoons per pound over four hours. Additional ORS is given to replace ongoing loss of stool as previously outlined. At the end of each hour, the patient's hydration status and continuing stool and emesis losses should be calculated, with the total hourly loss added to the amount to be given over the next hour.",
"     </li>",
"     <li>",
"      Maintenance phase &ndash; Once repletion is completed, feeding and fluids should be started as above. ORT is continued for ongoing diarrheal losses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Severe dehydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe dehydration is defined as 10 percent or greater volume loss.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Repletion phase &ndash; Severe dehydration is a medical emergency, and requires emergent intravenous therapy with rapid infusion of 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of isotonic saline. A more complete discussion on treatment of severe dehydration can be found elsewhere in the program. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link&amp;anchor=H3#H3\">",
"       \"Treatment of hypovolemia (dehydration) in children\", section on 'Emergent fluid phase'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      As the patient's clinical condition stabilizes and",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      level of consciousness returns to normal, therapy can be changed to ORT. A nasogastric tube can be used in patients who have a normal mental status but may be too weak to adequately drink the necessary volume of fluid. The intravenous line should remain in place until it is certain there is successful transition to ORT. ORT therapy is started at a volume of 100",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      (10 teaspoons per pound) over four hours. Additional ORS is given to replace ongoing loss of stool, as previously outlined. At the end of each hour, the patient's hydration status and continuing stool and emesis losses should be calculated, with the total hourly loss added to the amount to be given over the next hour.",
"     </li>",
"     <li>",
"      Maintenance phase &ndash; Once repletion is completed, feeding and fluids should be started as above. ORT is continued for ongoing diarrheal losses [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/33-52\">",
"       33-52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Composition of ORS preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1975, the WHO first introduced an ORS that subsequently has been used throughout the world for more than 25 years. This ORS, which was designed initially to treat children with diarrhea from cholera, has an osmolality of 311",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    and concentrations of glucose of 20",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    and sodium 90",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/9\">",
"     9",
"    </a>",
"    ]. This solution also has proven to be effective in hydrating children with diarrhea from different infectious agents and varying stool electrolyte losses. As an example, patients with rotavirus have stool losses of sodium ranging from 30 to 40",
"    <span class=\"nowrap\">",
"     mEq/L,",
"    </span>",
"    compared to those with cholera who have stool losses of sodium from 90 to 120",
"    <span class=\"nowrap\">",
"     mEq/L.",
"    </span>",
"   </p>",
"   <p>",
"    Despite",
"    this success with rehydration, an increased understanding of the pathophysiology of infectious diarrhea has led some investigators to conclude that the composition of the initial ORS could be optimized to help reduce the volume of stools and duration of diarrhea, as well as to decrease the potential risk of hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/9,16,33,34\">",
"     9,16,33,34",
"    </a>",
"    ]. Work therefore focused on two areas of research:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reducing the osmolality",
"     </li>",
"     <li>",
"      Modifying the type of carrier organic solute",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Osmolality",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large number of studies have demonstrated that a reduced osmolality solution reduces stool volume and the duration of diarrhea. A 2001 meta-analysis included 15 randomized controlled trials of 2397 patients with acute diarrhea of less than five days duration, which compared treatment with reduced-osmolality ORS (osmolality &le;250",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    to the then-standard WHO ORS (osmolality 311",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/38\">",
"     38",
"    </a>",
"    ]. Only three of the trials included cholera patients. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who received reduced-osmolality ORS, there were reductions in stool output, episodes of emesis, and the need for intravenous hydration as compared to patients who received the standard WHO ORS.",
"     </li>",
"     <li>",
"      In the three trials that measured serum sodium values, the incidence of hyponatremia was the same with both formulations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This meta-analysis was updated in 2002 with the addition of another study, which did not change the above findings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/39\">",
"     39",
"    </a>",
"    ]. An additional analysis demonstrated that ORT was associated with a lower rate of unscheduled IV fluid infusion.",
"   </p>",
"   <p>",
"    Based upon the finding in the initial meta-analysis, in 2002, the WHO changed the formulation of ORS to a lower osmolality (245",
"    <span class=\"nowrap\">",
"     mosmol/kg)",
"    </span>",
"    and to lower concentrations of glucose (13.5",
"    <span class=\"nowrap\">",
"     g/L",
"    </span>",
"    [75",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and sodium (75",
"    <span class=\"nowrap\">",
"     mEq/L).",
"    </span>",
"    This preserved the molar 1:1 ratio of sodium and glucose. This new formula replaces the original ORS, and is the only ORS used globally by the WHO.",
"   </p>",
"   <p>",
"    There remained concerns that the reduced-osmolality ORS may not be suitable for universal use, particularly in patients with cholera, because of the fear that replacing cholera diarrheal losses (sodium concentration of 90 to 120",
"    <span class=\"nowrap\">",
"     mEq/L)",
"    </span>",
"    with reduced-osmolality WHO ORS (sodium concentration of 75",
"    <span class=\"nowrap\">",
"     mEq/L)",
"    </span>",
"    would place patients in negative sodium balance, resulting in hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To determine whether reduced-osmolality WHO ORS results in an increased rate of symptomatic hyponatremia, a large observational study of 53,280 adults and children was conducted at two hospitals in Bangladesh [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/41\">",
"     41",
"    </a>",
"    ]. All patients admitted with uncomplicated watery diarrhea received reduced-osmolality WHO ORS. Patients who developed seizures or altered consciousness were evaluated to determine the cause of their symptoms (ie, hyponatremia, hypoglycemia, or hypernatremia). Stool samples were cultured from every fiftieth patient; 20 percent were positive for cholera.",
"   </p>",
"   <p>",
"    Data were compared to retrospective data from one of the sites from the previous year when the higher-osmolality WHO ORS was used. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall incidence of symptomatic hyponatremia (seizures or altered conscious, and a sodium concentration &lt;130",
"      <span class=\"nowrap\">",
"       mEq/L)",
"      </span>",
"      at the two sites using reduced-osmolality ORS was significantly lower than with the higher-osmolality ORS used in the previous year (0.03 to 0.05 versus 0.1 percent with higher-osmolality ORS).",
"     </li>",
"     <li>",
"      Symptomatic hyponatremia developed in 24 patients treated with reduced-osmolality ORS, all were &lt;3 years of age. In the comparison period, 47 patients developed symptomatic hyponatremia with the higher-osmolality ORS, 40 of whom were &lt;3 years of age.",
"     </li>",
"     <li>",
"      Infants &lt;6 months of age had the highest incidence of symptomatic hyponatremia (0.19 versus 0.10 percent in older infants and toddlers [7 to 36 months of age])",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results demonstrate that the incidence of symptomatic hyponatremia is rare in older children and adults, even in a study population where 20 percent of the patients were presumed to have cholera. In young children (&lt;3 years of age), symptomatic hyponatremia, although more frequent than the older population, was still uncommon. This trial demonstrated that the reduced-osmolality ORS is as safe as the previous formulation and can be used to treat most patients with acute diarrhea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Carrier organic solute",
"    </span>",
"    &nbsp;&mdash;&nbsp;As previously described, the physiologic basis of ORT is the sodium-coupled transport with a carrier organic solute, which was glucose. Based on this finding, polymer-based formulations were developed that replaced glucose with complex carbohydrates (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38865?source=see_link\">",
"     maltodextrin",
"    </a>",
"    or rice) or added other solutes to glucose, such as carrier amino acids. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Physiologic basis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In two meta-analyses, polymer-based ORS reduced stool output and duration of diarrhea in patients, particularly patients with cholera, compared to glucose-ORS [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/35,53\">",
"       35,53",
"      </a>",
"      ]. Most studies included in these reviews utilized glucose-ORS with osmolality &ge;310",
"      <span class=\"nowrap\">",
"       mosmol/kg.",
"      </span>",
"      However, polymer-based ORS also appeared to be associated with reduced stool volume compared to lower osmolar glucose-ORS (osmolality &le;270",
"      <span class=\"nowrap\">",
"       mosmol/kg),",
"      </span>",
"      but comparison data are limited. Until further data demonstrate that polymer-based ORS is significantly more beneficial than the currently standard ORS (osmolality &le;270",
"      <span class=\"nowrap\">",
"       mosmol/kg),",
"      </span>",
"      the CDC does not recommend polymer-based ORS as a first choice either in developing or developed countries as the standard WHO or commercial ORS, which are more readily available.",
"     </li>",
"     <li>",
"      Formulations that either used maltodextrins or added amino acids (glycine, alanine, and glutamine) to glucose are",
"      <strong>",
"       not",
"      </strong>",
"      more effective than standard ORS, and are more costly [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/34,36,37\">",
"       34,36,37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Zinc",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition, zinc supplementation should be administered in children with diarrhea in developing countries, in which there is a high prevalence of zinc deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/54\">",
"     54",
"    </a>",
"    ]. Zinc supplementation in these settings is discussed in greater detail elsewhere in the program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=see_link\">",
"     \"Persistent diarrhea in children in developing countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=see_link&amp;anchor=H14#H14\">",
"     \"Zinc deficiency and supplementation in children and adolescents\", section on 'Treatment of acute diarrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Commercial ORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercially available ORS vary in osmolality and sodium concentration (",
"    <a class=\"graphic graphic_table graphicRef67494 \" href=\"UTD.htm?5/30/5613\">",
"     table 1",
"    </a>",
"    ). All commercial ORS contain 2 to 3 percent carbohydrate, as glucose, rice, or other cereal; this amount is sufficient to maintain nutritional status in the short term (24 to 48 hours) while avoiding a large osmotic load in the intestinal lumen. Studies in the United States demonstrated successful treatment with commonly used commercial ORS in children with mild to moderate dehydration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In children between 5 and 10 years of age, sucralose-sweetened ORS solutions (eg, Pedialyte",
"    <sup>",
"     &reg;",
"    </sup>",
"    and Pediatric Electrolyte",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) appear to be more palatable than comparable rice-based solutions (eg, Enfalyte",
"    <sup>",
"     &reg;",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common household fluids such as gelatin, tea, fruit juice, sports drinks, and soft drinks have too little sodium, and nearly all have a much higher carbohydrate and osmolality content than recommended (",
"    <a class=\"graphic graphic_table graphicRef67494 \" href=\"UTD.htm?5/30/5613\">",
"     table 1",
"    </a>",
"    ). These fluids should",
"    <strong>",
"     not",
"    </strong>",
"    be used in children with diarrhea as they may increase diarrheal output and the incidence of hyponatremia. Other fluids, such as chicken soup, have a high sodium concentration, which may result in hypernatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/7,9\">",
"     7,9",
"    </a>",
"    ]; these also should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are clinical settings when ORT should not be used. These include children with the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered mental status with concern for aspiration",
"     </li>",
"     <li>",
"      Abdominal ileus",
"     </li>",
"     <li>",
"      Underlying disorder that limits intestinal absorption of ORT (eg, short gut, carbohydrate malabsorption)",
"     </li>",
"     <li>",
"      Severe dehydration (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Severe dehydration'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once ORT has been initiated, intervention with intravenous hydration is indicated:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If stool output continues to be excessive, and ORT is unable to adequately rehydrate the child",
"     </li>",
"     <li>",
"      If there is severe and persistent vomiting, and inadequate intake of ORS",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vomiting",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115057141\">",
"    <span class=\"h3\">",
"     Ondansetron",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with vomiting, a single oral dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    reduces vomiting, facilitates the administration of ORT, and reduces the need for intravenous fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. It is a useful adjunct to ORT and should be used to reduce vomiting in children with gastroenteritis who are receiving ORT.",
"   </p>",
"   <p>",
"    This was best illustrated in a systematic review of the literature that identified 11 trials of antiemetic drugs to reduce vomiting in children with gastroenteritis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/46\">",
"     46",
"    </a>",
"    ]. A meta-analysis of the six trials that compared",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    to placebo demonstrated the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In five trials,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"       ondansetron",
"      </a>",
"      compared to placebo was associated with a decreased risk of further vomiting (RR 0.45, 95% CI 0.28-0.62).",
"     </li>",
"     <li>",
"      In four trials,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"       ondansetron",
"      </a>",
"      was associated with a reduced need for intravenous fluids (RR 0.41, 95% CI 0.28-0.62).",
"     </li>",
"     <li>",
"      In five trials,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"       ondansetron",
"      </a>",
"      was associated with a decreased risk of immediate hospital admission (RR 0.52, 95% CI 0.28-0.62).",
"     </li>",
"     <li>",
"      In three trials,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"       ondansetron",
"      </a>",
"      increased diarrheal episodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    does not appear to increase the risk of missing other serious alternate causes of vomiting. This was illustrated in a large retrospective study from two pediatric emergencies departments (ED) that reviewed the records of 34,117 children with a diagnosis of vomiting or gastroenteritis, of whom 58 percent received ondansetron [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/56\">",
"     56",
"    </a>",
"    ]. Of the 76 children who were hospitalized with an alternate diagnosis after returning within 72 hours of discharge from the initial ED visit, there was no difference in the percentage of patients admitted between patients who received ondansetron and those who did not at the first ED visit (15 versus 22 percent). Alternate diagnoses included appendicitis, intussusception, bacteremia, pyelonephritis, small bowel obstruction, and intracranial tumor. This study also demonstrated that ondansetron reduced the rate of hospital admissions for gastroenteritis (3.7 versus 6.4 percent) but was associated with an increased likelihood of return to the ED (6.2 versus 4.7 percent).",
"   </p>",
"   <p>",
"    Electrocardiogram (ECG) interval changes are a class effect of the first-generation 5HT3 antagonists, including",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    . The Food and Drug Administration (FDA) has issued a warning about QTc prolongation and potentially fatal cardiac arrhythmias in patients treated with ondansetron [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/57\">",
"     57",
"    </a>",
"    ]. Ondansetron should be avoided in patients with congenital long-QT syndrome, and ECG monitoring should be used in patients at risk for QTc prolongation, including those with hypokalemia or hypomagnesemia, heart failure, bradyarrhythmias and in patients taking other medications that increase the risk of QTc prolongation (",
"    <a class=\"graphic graphic_table graphicRef57431 \" href=\"UTD.htm?2/48/2830\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In one of the included trials, the dosing for oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    was [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      2 mg for children weighing 8 to 15 kg",
"     </li>",
"     <li>",
"      4 mg for children weighing &gt;15 to 30 kg",
"     </li>",
"     <li>",
"      8 mg for children weighing &gt;30 kg",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon this study, the recommended dose is 0.1 to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    (maximum does of 8 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/58\">",
"     58",
"    </a>",
"    ]. Reported adverse effects include diarrhea, urticaria, headache, constipation, and fever. In addition,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    should not be used in patients who are at risk for malignant hyperthermia because of the potential for excessive serotonergic effect in these patients, which may be lethal [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115057148\">",
"    <span class=\"h3\">",
"     Other antiemetic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are too limited to reach any conclusions with other antiemetic agents including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/7/24692?source=see_link\">",
"     trimethobenzamide",
"    </a>",
"    , pyrilamine-pentobarbital,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/47/759?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/27/2487?source=see_link\">",
"     promethazine",
"    </a>",
"    . In one clinical trial, domperidone appears not to decrease the frequency of vomiting in children with acute gastroenteritis compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/60\">",
"     60",
"    </a>",
"    ]. In an earlier trial, although domperidone was associated with a decrease in episodes of vomiting compared with placebo, there was no difference in the primary outcome of weight gain between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/61\">",
"     61",
"    </a>",
"    ]. A large-scale trial comparing",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"     ondansetron",
"    </a>",
"    with domperidone is ongoing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Barriers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite its universal success in developing countries, ORT remains underutilized in the United States and other developed countries. Barriers include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lack of utilization and knowledge by medical providers &ndash; In a survey of American emergency medicine physicians, intravenous hydration continued to be the preferred treatment for moderate dehydration in children with gastroenteritis [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/47\">",
"       47",
"      </a>",
"      ]. Even 75 percent of physicians who indicated familiarity with the guidelines gave intravenous therapy to patients with moderate dehydration. In a second survey, pediatric emergency medicine fellowship directors preferred intravenous therapy, as they believed ORT to be more time-consuming for patients, families, and staff [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/48\">",
"       48",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Despite this preference, the results of a study that directly addressed many of these concerns found that ORT was superior to intravenous therapy in moderately dehydrated young children treated in an emergency department setting. In this prospective US study, 73 children with moderate dehydration were randomly assigned to ORT or intravenous therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/42\">",
"       42",
"      </a>",
"      ]. This study included only patients with verified moderate dehydration, and masked the treatment assignment; secondary outcome measures included time to initiate therapy and need for hospitalizations. In both groups, just over one-half of the patients were rehydrated by four hours. In the ORT group, patients required less time for therapy to be initiated, had fewer hospitalizations, and were better hydrated after two hours of therapy.",
"     </li>",
"     <li>",
"      Studies surveying pediatricians also have demonstrated a lack of compliance with the AAP guidelines. In one survey, less than 30 percent of respondents recommended ORT [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/49\">",
"       49",
"      </a>",
"      ]; instead, they recommended nonphysiologic fluids such as soda, popsicles, and tea. In a later survey of pediatricians attending a national continuing medical education conference, 30 percent of respondents stated they would withhold ORT in patients with vomiting or moderate dehydration, and only 3 percent recommended the use of a spoon or syringe to administer ORT [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/50\">",
"       50",
"      </a>",
"      ]. Fifty percent failed to advise prompt refeeding after the initial repletion phase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Expense &ndash; The cost of commercially available ORS may limit its use in low-socioeconomic families [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Public access to inaccurate information &ndash; There was one case report of a child whose care was compromised by following advice to use nonphysiologic fluids at a decreased rate from a hospital's Internet site [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18681/abstract/9,52\">",
"       9,52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       \"Patient information: Giving your child over-the-counter medicines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=see_link\">",
"       \"Patient information: Dehydration (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (See",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"       \"Patient information: Acute diarrhea in children (Beyond the Basics)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a summary of the above discussion regarding the use of ORT (",
"    <a class=\"graphic graphic_table graphicRef67494 \" href=\"UTD.htm?5/30/5613\">",
"     table 1",
"    </a>",
"    ) and is consistent with the guidelines published by the WHO, CDC, and AAP.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oral rehydration therapy is as effective as intravenous hydration in treating children with mild to moderate dehydration caused by diarrhea, and is the treatment of first choice in these patients.",
"     </li>",
"     <li>",
"      ORT is divided into rehydration and maintenance phases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rehydration &ndash; During the rehydration phase, the fluid deficit is replaced quickly over three to four hours. Oral rehydration solution is administrated in frequent small amounts, no more than 5 mL administered every one to two minutes by spoon or syringe, for a total of 50",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      in mild dehydration and 100",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      in moderate dehydration. If the patient is breast-fed, breastfeeding is maintained during the rehydration phase and is continued into the maintenance phase.",
"     </li>",
"     <li>",
"      Maintenance &ndash; During the maintenance phase, maintenance calories and fluids are administered. Rapid realimentation begins after completion of the rehydration phase, with the goal to return the patient to an age-appropriate unrestricted diet.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ongoing losses from diarrhea and vomiting are replaced with ORS. If the losses can be measured accurately, 1 mL of ORS should be administered for each gram of diarrheal stool. Alternatively, 10",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of body weight of ORS is administered for each watery or loose stool, and 2",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of body weight for each episode of emesis.",
"     </li>",
"     <li>",
"      In severe dehydration, emergent intravenous therapy is required with rapid infusion of 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of isotonic saline. Once the patient is stable, ORT can be started. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"       \"Treatment of hypovolemia (dehydration) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      ORT should not be used if the patient has an impaired mental status, abdominal ileus, or is unable to absorb fluid from the intestinal tract.",
"     </li>",
"     <li>",
"      Intravenous hydration should be initiated if the patient has persistent vomiting and is unable to adequately take ORT, or if ORT fails to rehydrate the patient.",
"     </li>",
"     <li>",
"      In children with gastroenteritis and persistent vomiting, we suggest a single dose of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/40/27272?source=see_link\">",
"       ondansetron",
"      </a>",
"      because it reduces vomiting, facilitates the administration of ORT, and decreases the need to intervene with intravenous fluids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). ECG interval changes appear to be a class effect of the first generation HT3 antagonists including ondansetron. Ondansetron should be avoided in patients with congenital long-QT syndrome, and ECG monitoring should be used in patients at risk for QTc prolongation, including those with hypokalemia or hypomagnesemia, heart failure, bradyarrhythmias. (See",
"      <a class=\"local\" href=\"#H115057141\">",
"       'Ondansetron'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonphysiologic fluids (eg, soda and juice) should be avoided for rehydration (",
"      <a class=\"graphic graphic_table graphicRef67494 \" href=\"UTD.htm?5/30/5613\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In the United States and other industrialized nations, ORT is the preferred treatment for the majority of children with mild and moderate dehydration, as it is safer and less expensive than intravenous treatment.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/1\">",
"      Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003; 81:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/2\">",
"      Parashar UD, Bresee JS, Glass RI. The global burden of diarrhoeal disease in children. Bull World Health Organ 2003; 81:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/3\">",
"      Bryce J, Boschi-Pinto C, Shibuya K, et al. WHO estimates of the causes of death in children. Lancet 2005; 365:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/4\">",
"      Victora CG, Bryce J, Fontaine O, Monasch R. Reducing deaths from diarrhoea through oral rehydration therapy. Bull World Health Organ 2000; 78:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/5\">",
"      Santosham M, Keenan EM, Tulloch J, et al. Oral rehydration therapy for diarrhea: an example of reverse transfer of technology. Pediatrics 1997; 100:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/6\">",
"      Duggan C, Lasche J, McCarty M, et al. Oral rehydration solution for acute diarrhea prevents subsequent unscheduled follow-up visits. Pediatrics 1999; 104:e29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/7\">",
"      Practice parameter: the management of acute gastroenteritis in young children. American Academy of Pediatrics, Provisional Committee on Quality Improvement, Subcommittee on Acute Gastroenteritis. Pediatrics 1996; 97:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/8\">",
"      Avery ME, Snyder JD. Oral therapy for acute diarrhea. The underused simple solution. N Engl J Med 1990; 323:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/9\">",
"      King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/10\">",
"      HARRISON HE. The treatment of diarrhea in infancy. Pediatr Clin North Am 1954; :335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/11\">",
"      DARROW DC. The retention of electrolyte during recovery from severe dehydration due to diarrhea. J Pediatr 1946; 28:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/12\">",
"      Paneth N. Hypernatremic dehydration of infancy: an epidemiologic review. Am J Dis Child 1980; 134:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/13\">",
"      Schultz SG, Fuisz RE, Curran PF. Amino acid and sugar transport in rabbit ileum. J Gen Physiol 1966; 49:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/14\">",
"      Hirschhorn N, Kinzie JL, Sachar DB, et al. Decrease in net stool output in cholera during intestinal perfusion with glucose-containing solutions. N Engl J Med 1968; 279:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/15\">",
"      Pierce NF, Sack RB, Mitra RC, et al. Replacement of water and electrolyte losses in cholera by an oral glucose-electrolyte solution. Ann Intern Med 1969; 70:1173.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Reduced osmolarity oral rehydration salts (ORS) formulation. UNICEF House, New York, NY 2001. Available at: www.who.int/child-adolescent-health/New_Publications/NEWS/Expert_consultation.htm (Accessed on January 18, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/17\">",
"      Mahalanabis D, Choudhuri AB, Bagchi NG, et al. Oral fluid therapy of cholera among Bangladesh refugees. Johns Hopkins Med J 1973; 132:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/18\">",
"      Santosham M, Daum RS, Dillman L, et al. Oral rehydration therapy of infantile diarrhea: a controlled study of well-nourished children hospitalized in the United States and Panama. N Engl J Med 1982; 306:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/19\">",
"      Tamer AM, Friedman LB, Maxwell SR, et al. Oral rehydration of infants in a large urban U.S. medical center. J Pediatr 1985; 107:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/20\">",
"      Listernick R, Zieserl E, Davis AT. Outpatient oral rehydration in the United States. Am J Dis Child 1986; 140:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/21\">",
"      Vesikari T, Isolauri E, Baer M. A comparative trial of rapid oral and intravenous rehydration in acute diarrhoea. Acta Paediatr Scand 1987; 76:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/22\">",
"      Atherly-John YC, Cunningham SJ, Crain EF. A randomized trial of oral vs intravenous rehydration in a pediatric emergency department. Arch Pediatr Adolesc Med 2002; 156:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/23\">",
"      Fonseca BK, Holdgate A, Craig JC. Enteral vs intravenous rehydration therapy for children with gastroenteritis: a meta-analysis of randomized controlled trials. Arch Pediatr Adolesc Med 2004; 158:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/24\">",
"      Hartling L, Bellemare S, Wiebe N, et al. Oral versus intravenous rehydration for treating dehydration due to gastroenteritis in children. Cochrane Database Syst Rev 2006; :CD004390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/25\">",
"      Munos MK, Walker CL, Black RE. The effect of oral rehydration solution and recommended home fluids on diarrhoea mortality. Int J Epidemiol 2010; 39 Suppl 1:i75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/26\">",
"      Guarino A, Albano F, Ashkenazi S, et al. European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr 2008; 46 Suppl 2:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/27\">",
"      Stanton BF, Rowland MG, Clemens JD. Oral rehydration solution--too little or too much? Lancet 1987; 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/28\">",
"      Meyers A, Sampson A, Saladino R, et al. Safety and effectiveness of homemade and reconstituted packet cereal-based oral rehydration solutions: a randomized clinical trial. Pediatrics 1997; 100:E3.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. The treatment of diarrhea: a manual for physicians and other senior health workers. World Health Organization, Geneva, Switzerland 1995. Available at: www.who.int/child-adolescent-health/New_Publications/CHILD_HEALTH/ISBN_92_4_159318_0.pdf (Accessed on September 14, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/30\">",
"      Mackenzie A, Barnes G. Randomised controlled trial comparing oral and intravenous rehydration therapy in children with diarrhoea. BMJ 1991; 303:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/31\">",
"      Gremse DA. Effectiveness of nasogastric rehydration in hospitalized children with acute diarrhea. J Pediatr Gastroenterol Nutr 1995; 21:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/32\">",
"      Nager AL, Wang VJ. Comparison of nasogastric and intravenous methods of rehydration in pediatric patients with acute dehydration. Pediatrics 2002; 109:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/33\">",
"      Fayad IM, Hirschhorn N, Abu-Zikry M, Kamel M. Hypernatraemia surveillance during a national diarrhoeal diseases control project in Egypt. Lancet 1992; 339:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/34\">",
"      Duggan C, Fontaine O, Pierce NF, et al. Scientific rationale for a change in the composition of oral rehydration solution. JAMA 2004; 291:2628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/35\">",
"      Gore SM, Fontaine O, Pierce NF. Impact of rice based oral rehydration solution on stool output and duration of diarrhoea: meta-analysis of 13 clinical trials. BMJ 1992; 304:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/36\">",
"      Bhan MK, Mahalanabis D, Fontaine O, Pierce NF. Clinical trials of improved oral rehydration salt formulations: a review. Bull World Health Organ 1994; 72:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/37\">",
"      Nalin DR, Cash RA, Rahman M, Yunus M. Effect of glycine and glucose on sodium and water adsorption in patients with cholera. Gut 1970; 11:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/38\">",
"      Hahn S, Kim Y, Garner P. Reduced osmolarity oral rehydration solution for treating dehydration due to diarrhoea in children: systematic review. BMJ 2001; 323:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/39\">",
"      Hahn S, Kim S, Garner P. Reduced osmolarity oral rehydration solution for treating dehydration caused by acute diarrhoea in children. Cochrane Database Syst Rev 2002; :CD002847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/40\">",
"      Nalin DR, Hirschhorn N, Greenough W 3rd, et al. Clinical concerns about reduced-osmolarity oral rehydration solution. JAMA 2004; 291:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/41\">",
"      Alam NH, Yunus M, Faruque AS, et al. Symptomatic hyponatremia during treatment of dehydrating diarrheal disease with reduced osmolarity oral rehydration solution. JAMA 2006; 296:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/42\">",
"      Spandorfer PR, Alessandrini EA, Joffe MD, et al. Oral versus intravenous rehydration of moderately dehydrated children: a randomized, controlled trial. Pediatrics 2005; 115:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/43\">",
"      Cohen MB, Mezoff AG, Laney DW Jr, et al. Use of a single solution for oral rehydration and maintenance therapy of infants with diarrhea and mild to moderate dehydration. Pediatrics 1995; 95:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/44\">",
"      Freedman SB, Adler M, Seshadri R, Powell EC. Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med 2006; 354:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/45\">",
"      Roslund G, Hepps TS, McQuillen KK. The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial. Ann Emerg Med 2008; 52:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/46\">",
"      DeCamp LR, Byerley JS, Doshi N, Steiner MJ. Use of antiemetic agents in acute gastroenteritis: a systematic review and meta-analysis. Arch Pediatr Adolesc Med 2008; 162:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/47\">",
"      Ozuah PO, Avner JR, Stein RE. Oral rehydration, emergency physicians, and practice parameters: a national survey. Pediatrics 2002; 109:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/48\">",
"      Conners GP, Barker WH, Mushlin AI, Goepp JG. Oral versus intravenous: rehydration preferences of pediatric emergency medicine fellowship directors. Pediatr Emerg Care 2000; 16:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/49\">",
"      Snyder JD. Use and misuse of oral therapy for diarrhea: comparison of US practices with American Academy of Pediatrics recommendations. Pediatrics 1991; 87:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/50\">",
"      Reis EC, Goepp JG, Katz S, Santosham M. Barriers to use of oral rehydration therapy. Pediatrics 1994; 93:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/51\">",
"      Meyers A, Siegel B, Vinci R. Economic barriers to the use of oral rehydration therapy. A case report. JAMA 1991; 265:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/52\">",
"      Crocco AG, Villasis-Keever M, Jadad AR. Two wrongs don't make a right: harm aggravated by inaccurate information on the Internet. Pediatrics 2002; 109:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/53\">",
"      Gregorio GV, Gonzales ML, Dans LF, Martinez EG. Polymer-based oral rehydration solution for treating acute watery diarrhoea. Cochrane Database Syst Rev 2009; :CD006519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/54\">",
"      Suh JS, Hahn WH, Cho BS. Recent Advances of Oral Rehydration Therapy (ORT). Electrolyte Blood Press 2010; 8:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/55\">",
"      Freedman SB, Cho D, Boutis K, et al. Assessing the palatability of oral rehydration solutions in school-aged children: a randomized crossover trial. Arch Pediatr Adolesc Med 2010; 164:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/56\">",
"      Sturm JJ, Hirsh DA, Schweickert A, et al. Ondansetron use in the pediatric emergency department and effects on hospitalization and return rates: are we masking alternative diagnoses? Ann Emerg Med 2010; 55:415.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm272041.htm (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/58\">",
"      Levine DA. Antiemetics for acute gastroenteritis in children. Curr Opin Pediatr 2009; 21:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/59\">",
"      Gener B, Burns JM, Griffin S, Boyer EW. Administration of ondansetron is associated with lethal outcome. Pediatrics 2010; 125:e1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/60\">",
"      Gouin S, Vo TT, Roy M, et al. Oral dimenhydrinate versus placebo in children with gastroenteritis: a randomized controlled trial. Pediatrics 2012; 129:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/61\">",
"      Uhlig U, Pfeil N, Gelbrich G, et al. Dimenhydrinate in children with infectious gastroenteritis: a prospective, RCT. Pediatrics 2009; 124:e622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18681/abstract/62\">",
"      Marchetti F, Maestro A, Rovere F, et al. Oral ondansetron versus domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial. BMC Pediatr 2011; 11:15.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6129 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C801F8800B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18681=[""].join("\n");
var outline_f18_15_18681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHYSIOLOGIC BASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Home",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Medical setting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ORT based on degree of dehydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - No dehydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Mild dehydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Moderate dehydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Severe dehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Composition of ORS preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Osmolality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Carrier organic solute",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Zinc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Commercial ORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vomiting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H115057141\">",
"      - Ondansetron",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H115057148\">",
"      - Other antiemetic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Barriers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6129\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6129|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/30/5613\" title=\"table 1\">",
"      Composition ORS beverages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/5/13404\" title=\"table 2\">",
"      Pediatric signs of dehydration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/4/37963\" title=\"table 3\">",
"      ORT replacement guide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/48/2830\" title=\"table 4\">",
"      Causes of long QT syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=related_link\">",
"      Evaluation of diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/53/15188?source=related_link\">",
"      Pathogenesis of acute diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=related_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/62/32738?source=related_link\">",
"      Patient information: Dehydration (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=related_link\">",
"      Persistent diarrhea in children in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9912?source=related_link\">",
"      Prevention and treatment of viral gastroenteritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_15_18682="Evaluation of syncope in adults";
var content_f18_15_18682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of syncope in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/15/18682/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18682/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/15/18682/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18682/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18682/contributors\">",
"     Robert S Hockberger, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/15/18682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/15/18682/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/15/18682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope is the abrupt and transient loss of consciousness associated with absence of postural tone, followed by complete and usually rapid spontaneous recovery. Syncope is alarming for the individual, witnesses, family, and physicians.",
"   </p>",
"   <p>",
"    Syncope is most often benign and self-limited, although it can be a harbinger of a multitude of disease processes. Injuries resulting from syncopal attacks occur in about one-third of patients, and recurrent episodes can be psychologically devastating. In addition, syncope can be a premonitory sign of cardiac arrest, especially in patients with organic heart disease.",
"   </p>",
"   <p>",
"    Issues relating to the evaluation of syncope in adults will be reviewed here. The pathogenesis, etiology, and management of this disorder in adults are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link\">",
"     \"Pathogenesis and etiology of syncope\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28855?source=see_link\">",
"     \"Management of the patient with syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause for syncope is often not obvious, and it can be difficult to identify the individual at risk for sudden death (",
"    <a class=\"graphic graphic_table graphicRef64301 \" href=\"UTD.htm?8/31/8701\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]. A prospective study of 341 patients found the following distribution of causes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reflex (neurally-mediated; this includes vasovagal) &mdash; 58 percent",
"     </li>",
"     <li>",
"      Cardiac disease, most often a bradyarrhythmia or tachyarrhythmia &mdash; 23 percent",
"     </li>",
"     <li>",
"      Neurologic or psychiatric disease &mdash; 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unexplained syncope &mdash; 18 percent; a higher value (41 percent) was noted in another large series [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Syncope should be differentiated from nonsyncopal conditions that produce apparent or real transient loss of consciousness (eg, falls, transient ischemic attacks) (",
"    <a class=\"graphic graphic_table graphicRef76023 \" href=\"UTD.htm?23/58/24491\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also important to distinguish syncope from cardiac arrest. Patients with loss of consciousness requiring cardiopulmonary resuscitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    electric or pharmacologic cardioversion should be diagnosed as having cardiac arrest and not syncope. However, these two diagnostic entities are related, since patients with cardiac syncope have a high incidence of subsequent cardiac arrest (approximately 24 percent in one year in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strategies for the evaluation of syncope were outlined in guidelines published by the European Society of Cardiology (ESC) in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ] and in a 2006 scientific statement from the American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of Cardiology",
"    <span class=\"nowrap\">",
"     (AHA/ACC)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of the patient with syncope is the same as that for presyncope, which is the prodromal symptom of fainting. Such patients usually present with symptoms of dizziness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=see_link\">",
"     \"Approach to the patient with dizziness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14005354\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying etiology for syncope can often be identified from the initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1,4-7\">",
"     1,4-7",
"    </a>",
"    ]. Information obtained from the initial evaluation can appropriately guide further analysis if the cause remains unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. Algorithms to diagnose the cause of syncope have been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ], but no protocol identifies a cause in all patients with syncope.",
"   </p>",
"   <p>",
"    The efficacy of initial clinical evaluation was illustrated in a study of 650 patients who presented to the emergency department with syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/5\">",
"     5",
"    </a>",
"    ]. The initial clinical evaluation, including carotid sinus massage, ECG, and basic laboratory testing, established a suspected cause of syncope in 69 percent; among the 67 patients who underwent targeted tests when a specific cause was clinically suspected, a diagnosis was established in 73 percent. In contrast, among 122 of the remaining patients in whom clinical evaluation and targeted testing were inconclusive, an extensive cardiovascular workup established the cause in only 25 percent.",
"   </p>",
"   <p>",
"    As noted in the 2009 ESC guidelines, initial evaluation of the patient presenting with transient loss of consciousness should include careful history, physical examination (including orthostatic blood pressure measurement), and electrocardiogram [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial evaluation should answer three key questions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is it a syncopal episode or other type of event?",
"     </li>",
"     <li>",
"      Has the etiology been determined?",
"     </li>",
"     <li>",
"      Is there evidence suggestive of a high risk of cardiovascular events or death? (",
"      <a class=\"graphic graphic_table graphicRef78397 \" href=\"UTD.htm?20/26/20908\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features associated with a syncopal event are important and may be diagnostic (",
"    <a class=\"graphic graphic_table graphicRef55096 \" href=\"UTD.htm?29/30/30188\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"     table 5",
"    </a>",
"    ). [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1,4,8,9\">",
"     1,4,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16427295\">",
"    <span class=\"h3\">",
"     Type of episode",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following questions can help determine whether the episode was syncope or a non-syncopal event with real or apparent loss of consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Was loss of consciousness complete?",
"     </li>",
"     <li>",
"      Was loss of consciousness transient with rapid onset and short duration?",
"     </li>",
"     <li>",
"      Did the patient recover spontaneously, completely and without sequelae?",
"     </li>",
"     <li>",
"      Did the patient lose postural tone?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the answer to all of the above questions is yes, the episode is likely to be syncope. If one or more answers is no, other forms of loss of consciousness should be excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Number of episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign causes of syncope are associated with a single syncopal episode in most patients, but some have multiple episodes over many years. By comparison, the patient with multiple episodes occurring over a short period of time is more likely to suffer from a serious underlying disorder.",
"   </p>",
"   <p>",
"    The number of syncopal episodes can predict the risk of recurrence. This was illustrated in a series of 80 patients in which 90 percent of those with a single episode of syncope remained free of recurrence at 23 months without medical therapy and irrespective of the results of a tilt table test [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, 54 percent of patients with two or more syncopal episodes suffered a recurrent episode.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Associated symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms occurring in association with syncope can point toward a specific cause (",
"    <a class=\"graphic graphic_table graphicRef55096 \" href=\"UTD.htm?29/30/30188\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]. As examples, dyspnea may suggest an acute pulmonary embolism; angina frequently indicates an underlying cardiac cause; a history of focal neurologic abnormalities favors a neurologic origin; and urinary",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fecal incontinence suggest, but do not prove, a seizure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Prodrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Auras\" are associated with seizures. In comparison, vasovagal (neurocardiogenic) syncope is usually, but not always, associated with a prodrome of nausea, warmth, pallor, lightheadedness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diaphoresis. Such symptoms may also occur without an episode of syncope. Older individuals with vasovagal syncope are less likely to experience a prodrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Sudden onset",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sudden onset of syncope without a prodrome is more common among patients with cardiac syncope (arrhythmic or mechanical cardiac etiology) than among patients with non-cardiac syncope. However, since non-cardiac syncope is far more common than cardiac syncope, the majority of patients with sudden onset of syncope have a non-cardiac cause. In a study of 260 patients presenting with syncope to emergency departments, no prodrome was identified in 52 percent of patients with cardiac syncope (mostly arrhythmic) versus 26 percent of patients with noncardiac (largely reflex) syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/11\">",
"     11",
"    </a>",
"    ]. However, most patients with sudden onset of syncope had a non-cardiac cause (56 patients with non-cardiac syncope versus 23 with cardiac syncope).",
"   </p>",
"   <p>",
"    In a study of 85 patients with recurrent unexplained syncope, patients were monitored by an implantable loop recorder. An arrhythmic etiology was present in 64 percent of sudden syncopal events [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/12\">",
"     12",
"    </a>",
"    ]. In contrast, presyncope (lightheadedness, dizziness, vertigo, unsteadiness) was a nonspecific symptom that was associated with sinus rhythm in 75 percent of episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Position",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurocardiogenic syncope commonly occurs when the patient is erect, not usually when supine. Syncope resulting from orthostatic hypotension is frequently associated with the change from a supine to erect posture. In comparison, syncope that occurs when the patient is supine suggests an arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16427389\">",
"    <span class=\"h3\">",
"     Provocative factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Situational syncope is a type of reflex (neurally-mediated) syncope that occurs during or immediately after provocative stimuli such as coughing, swallowing (particularly cold liquid), crowded or warm places, prolonged standing, post-prandial state, fear, intense pain, urinating, or defecating [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A vagal \"surge\" immediately upon swallowing can cause bradycardia and hypotension in predisposed patients. Postprandial hypotension may also reflect inadequate sympathetic compensation to meal-induced splanchnic pooling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=see_link\">",
"     \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neck movements can precipitate carotid sinus syncope, a type of reflex syncope caused by hypersensitivity of the carotid sinus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=see_link\">",
"     \"Carotid sinus hypersensitivity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1381002\">",
"    <span class=\"h3\">",
"     Exertional syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evaluation to rule out potentially life-threatening causes for syncope is required if syncope occurs during exertion. Among the pathologic causes of exertional syncope are ventricular tachycardia and obstruction resulting from aortic stenosis or hypertrophic cardiomyopathy, and hypotension due to vagally-mediated vasodepression in patients with hypertrophic cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Syncope associated with exercise also occurs in patients, usually young, who do not have underlying heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. If exertional syncope has occurred, neurocardiogenic syncope, while not uncommon, is diagnosed after exclusion of other causes. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=see_link&amp;anchor=H2#H2\">",
"     \"Arrhythmia in athletes\", section on 'Syncope'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Duration of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prolonged loss of consciousness may indicate a seizure. By comparison, arrhythmias and neurocardiogenic syncope are often associated with a brief period of syncope, since the supine position reestablishes some blood flow to the brain and can therefore result in the restoration of consciousness. Recovery of consciousness may occur even if the arrhythmia is maintained.",
"   </p>",
"   <p>",
"    Persistence of nausea, pallor, and diaphoresis in addition to a prolonged recovery from the episode suggest a vagal event. These findings are helpful in distinguishing neurocardiogenic syncope from syncope due to an arrhythmia. Significant neurologic changes or confusion during the recovery period may be due to a stroke or seizure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Witnessed signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A witness to the syncopal event may verify the loss of consciousness, any associated limb movements, and the presence or absence of pallor, diaphoresis, or a pulse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurocardiogenic syncope is more likely to occur among young, otherwise healthy patients. However, syncope resulting from the long QT syndrome or hypertrophic cardiomyopathy can also occur in young individuals. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Preexisting medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical conditions can predispose a patient to syncope or can favor a specific cause. As examples, patients with psychiatric illness may have syncope secondary to hyperventilation, panic attacks, or medications; syncope in a patient with diabetes mellitus may result from orthostatic hypotension secondary to autonomic neuropathy; and antihypertensive medications can result in syncope. In addition, the presence of heart disease strongly implies a cardiac cause for syncope. Relevant neurological history includes history of epilepsy or narcolepsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1939366\">",
"    <span class=\"h3\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important elements of the family history include history of sudden death, cardiomyopathy, or fainting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury does not predict a cause for syncope. Although injury is not necessarily predictive of a malignant life-threatening cause for syncope, some investigators have suggested that patients who have a significant injury with syncope have a high mortality rate. This apparent paradox may be due to the fact that among those with tachyarrhythmias, injury identifies those with significant hemodynamic compromise. Syncope can also result from injury if the pain triggers a neurocardiogenic response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Medications or recreational drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications can cause syncope, especially antiarrhythmic (proarrhythmic effects) and antihypertensive agents (primarily due to orthostatic hypotension with sympathetic blockers). The abuse of illicit drugs or alcohol also has been associated with syncope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Distinction of syncope from seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures are the probable cause of 5 to 15 percent of apparent syncopal episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. They can mimic syncope when the seizure is atypical and not associated with tonic-clonic movements, the seizure is not observed, or a complete history cannot be obtained (",
"    <a class=\"graphic graphic_table graphicRef73515 \" href=\"UTD.htm?36/6/36973\">",
"     table 6",
"    </a>",
"    ). In addition, some patients with syncope present with myoclonic or other involuntary movements that are suggestive of a seizure but are actually due to cerebral hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One distinguishing feature is that patients with seizures rarely have a rapid and complete recovery. Instead, the postictal state is characterized by a slow and complete recovery. Other features that distinguish syncope from seizures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonepileptic paroxysmal disorders in adolescents and adults\", section on 'Syncope'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of findings on physical examination can aid in the identification of some of the common causes of syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Abnormal vital signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood pressure obtained in the supine, sitting, and erect position may detect orthostatic hypotension. (See",
"    <a class=\"local\" href=\"#H1939581\">",
"     'Orthostatic challenge'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Disturbances in heart rhythm or breathing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heart rate may be rapid or slow due to a number of possible rhythm disturbances, or irregular due to atrial fibrillation. The pulse and blood pressure should be obtained with the patient supine, seated, and erect. Hyperventilation can be seen with pulmonary embolism or psychiatric causes of syncope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cardiac auscultatory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiac examination may reveal the murmur of aortic stenosis, pulmonic stenosis, or atrial myxoma. Pulmonary hypertension may be suggested by a loud, palpable P2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Physiologic maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increase in an outflow murmur with the Valsalva maneuver may help diagnose hypertrophic cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=see_link\">",
"     \"Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Abnormal neurologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral abnormalities found upon neurologic examination may reflect a cerebral vascular accident.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Gastrointestinal bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive stool guaiac generally indicates gastrointestinal blood loss, which can result sequentially in anemia, hypovolemia, and syncope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;An electrocardiogram (ECG) should be obtained in all patients with syncope. The ECG is suggestive of an arrhythmic cause of syncope if any of the following abnormalities is present (",
"    <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bifascicular block (defined as left bundle branch block or right bundle branch block combined with left anterior or left posterior fascicular block)",
"     </li>",
"     <li>",
"      Other intraventricular conduction abnormalities (QRS duration &ge;0.12 sec)",
"     </li>",
"     <li>",
"      Mobitz I second degree atrioventricular block",
"     </li>",
"     <li>",
"      Asymptomatic sinus bradycardia (&lt;50",
"      <span class=\"nowrap\">",
"       beats/min),",
"      </span>",
"      sinoatrial block or sinus pause &ge;3 seconds in the absence of negatively chronotropic medications",
"     </li>",
"     <li>",
"      Preexcited QRS complexes, suggesting Wolff-Parkinson-White syndrome",
"     </li>",
"     <li>",
"      Long or short QT intervals",
"     </li>",
"     <li>",
"      Right bundle branch block pattern with ST-elevation in leads V1-V3 (Brugada syndrome)",
"     </li>",
"     <li>",
"      Negative T waves in right precordial leads, epsilon waves and ventricular late potentials suggestive of arrhythmogenic right ventricular cardiomyopathy",
"     </li>",
"     <li>",
"      Q waves suggesting myocardial infarction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certain electrocardiographic features are suggestive of high risk (",
"    <a class=\"graphic graphic_table graphicRef78397 \" href=\"UTD.htm?20/26/20908\">",
"     table 3",
"    </a>",
"    ). As an example, a prolonged QT interval on electrocardiogram favors torsades de pointes as a possible underlying cause for syncope. However, patients with the long QT syndrome may have a normal QT interval at baseline; a diagnostic clue to the presence of this abnormality is that the QT interval can fail to shorten or may actually increase upon exercising. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other possible causes of syncope that can be diagnosed from or suggested by the electrocardiogram include chronic obstructive pulmonary disease and hypertrophic cardiomyopathy. However, the presence of an abnormal ECG is not proof of causality, especially if the patient is asymptomatic at the time of the recording. A prolonged rhythm strip of 30 to 60 seconds in length may be useful diagnostically, especially if the patient is symptomatic at the time of recording.",
"   </p>",
"   <p>",
"    Certain ECG findings are considered diagnostic. The 2009 ESC guidelines list the following as diagnostic of arrhythmia-related syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Persistent sinus bradycardia &lt;40",
"      <span class=\"nowrap\">",
"       beats/minute",
"      </span>",
"      in an awake patient or repetitive sinoatrial blocks or sinus pauses &gt;3 seconds",
"     </li>",
"     <li>",
"      Mobitz II second or third degree atrioventricular block",
"     </li>",
"     <li>",
"      Alternating left and right bundle branch block",
"     </li>",
"     <li>",
"      Ventricular tachycardia or rapid paroxysmal supraventricular tachycardia",
"     </li>",
"     <li>",
"      Pacemaker or implantable cardioverter-defibrillator malfunction with cardiac pauses",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16427095\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the diagnosis is uncertain following the initial evaluation, further evaluation and management should be guided by risk stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If clinical features of high risk of short-term serious event are present, early evaluation and treatment are indicated. Short-term, high-risk criteria indicate need for intensive evaluation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prompt hospitalization. The following are high-risk features (",
"      <a class=\"graphic graphic_table graphicRef78397 \" href=\"UTD.htm?20/26/20908\">",
"       table 3",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Evidence of significant heart disease (such as heart failure, low left ventricular ejection fraction, or previous myocardial infarction).",
"     </li>",
"     <li>",
"      Clinical or electrocardiographic (ECG) features suggesting arrhythmic syncope (",
"      <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"       table 5",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Certain comorbidities such as severe anemia or electrolyte disturbance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If there are single or rare episodes of syncope with low risk clinical features, no further evaluation is indicated.",
"     </li>",
"     <li>",
"      If there are recurrent episodes with low risk features, work-up should include tests for cardiac or neurally-mediated causes, as appropriate (",
"      <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"       table 5",
"      </a>",
"      ). Treatment may be deferred and should be guided by the results of ECG documentation and other tests. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The potential role of brain natriuretic peptide in risk stratification is discussed below. (See",
"    <a class=\"local\" href=\"#H1382541\">",
"     'Brain natriuretic peptide'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional testing is based on the results of the initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]. A variety of tests, mostly cardiologic, can be used in the evaluation of the patient with syncope. Neurologic testing is generally of low yield and overused, unless specifically suggested by history or physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2009 ESC guidelines recommended the following testing strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carotid sinus massage in patients &gt;40 years old.",
"     </li>",
"     <li>",
"      Echocardiogram when there is previous known heart disease or data suggestive of structural heart disease or syncope secondary to cardiovascular cause (",
"      <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Immediate ECG monitoring when there is a suspicion of arrhythmic syncope (",
"      <a class=\"graphic graphic_table graphicRef78397 \" href=\"UTD.htm?20/26/20908\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Electrocardiographic monitoring'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Orthostatic challenge (lying to standing orthostatic test or head-up tilt testing) when syncope is related to the standing position or there is suspicion of a reflex mechanism",
"     </li>",
"     <li>",
"      Other less specific tests such as neurological evaluation or blood tests are indicated only when there is suspicion of non-syncopal transient loss of consciousness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1939404\">",
"    <span class=\"h2\">",
"     Carotid sinus massage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid sinus hypersensitivity, which is responsible for the carotid sinus syndrome, can be demonstrated by careful carotid sinus massage. The 2009 ESC guidelines recommend carotid sinus massage in patients over age 40 with syncope of unknown etiology after the initial evaluation (",
"    <a class=\"graphic graphic_table graphicRef69426 \" href=\"UTD.htm?34/25/35227\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]. Carotid sinus massage should be avoided in patients with history of transient ischemic attack or stroke within the past three months and in patients with carotid bruits (except if carotid Doppler studies excluded significant stenosis).",
"   </p>",
"   <p>",
"    Carotid sinus massage is diagnostic if syncope is reproduced together with asystolic longer than 3s",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a fall in systolic BP &gt;50 mmHg.",
"   </p>",
"   <p>",
"    Contraindications, complications, and the procedure for carotid sinus massage are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=see_link\">",
"     \"Vagal maneuvers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1939581\">",
"    <span class=\"h2\">",
"     Orthostatic challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 ESC syncope guidelines describe two methods for assessing the response to change in posture from supine to erect: active standing and tilt testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1939497\">",
"    <span class=\"h3\">",
"     Active standing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Orthostatic blood pressure measurement is performed with the patient standing after at least five minutes of lying supine. Blood pressure should be measured each minute (or more often) in the standing position for three minutes or more (or as long as the patient tolerates) until the blood pressure nadir is reached. A sphygmomanometer (manual blood pressure cuff) may allow greater flexibility than an automatic arm-cuff device in measuring blood pressure prior to and during active standing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1939518\">",
"    <span class=\"h3\">",
"     Tilt testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tilt testing is commonly performed for the evaluation of syncope, although the test has limited specificity, sensitivity, and reproducibility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27399?source=see_link\">",
"     \"Upright tilt table testing in the evaluation of syncope\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1380566\">",
"    <span class=\"h2\">",
"     Orthostatic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 ESC guidelines identify six orthostatic syndromes, of which the first five are causes of syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic orthostatic hypotension (OH) is defined as a decrease in systolic blood pressure (BP) of &ge;20 mmHg and in diastolic BP &ge;10 mmHg within three minutes of standing. This syndrome is diagnosed by active standing or tilt testing.",
"     </li>",
"     <li>",
"      Initial OH is defined by a BP decrease immediately on standing of &gt;40 mmHg with BP spontaneously and rapidly returning to normal, so the period of hypotension and symptoms is &lt;30 s. This is diagnosed by active standing.",
"     </li>",
"     <li>",
"      Reflex syncope (vasovagal syncope) triggered by standing is characterized by an initial normal adaption reflex followed by rapid fall in venous return and vasovagal reaction (reflex bradycardia and vasodilatation). This is diagnosed by tilt table.",
"     </li>",
"     <li>",
"      Delayed (progressive) OH is defined by a slow progressive decrease in systolic BP on standing with no bradycardic reflex (in contrast to reflex syncope). This is diagnosed by tilt table.",
"     </li>",
"     <li>",
"      Delayed (progressive) OH plus reflex syncope occurs when a vasovagal reaction (reflex bradycardia and vasodilation) follows delayed OH. This is diagnosed by tilt table.",
"     </li>",
"     <li>",
"      Postural orthostatic tachycardia syndrome (POTS) presents with severe orthostatic intolerance (not syncope) with marked increase in heart rate (by &gt;30 beats per minute or to &gt;120 beats per minute) and instability of BP. This is diagnosed by tilt table. This syndrome is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29159?source=see_link\">",
"       \"Postural tachycardia syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the 2009 ESC and 2006",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    guidelines, echocardiography is recommended in patients with syncope when structural cardiac disease is suspected (",
"    <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Assessment of cardiac substrate may also help stratify risk. Echocardiography can diagnose underlying structural heart disease such as left ventricular dysfunction, hypertrophic cardiomyopathy, or significant aortic stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/19\">",
"     19",
"    </a>",
"    ]. It may also suggest pulmonary embolism if pulmonary hypertension or right ventricular enlargement is present [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the finding of structural heart disease does",
"    <strong>",
"     not",
"    </strong>",
"    generally establish the etiology for syncope and usually other tests are indicated to determine the cause. As noted in the ESC guidelines, only a finding of severe aortic stenosis, obstructive tumor or thrombus (eg, atrial myxoma), cardiac tamponade, aortic dissection, or congenital anomaly of the coronary artery is considered diagnostic as a cause for syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Electrocardiographic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiographic (ECG) monitoring is indicated if there is a high probability of identifying an arrhythmia associated with syncope (",
"    <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In-hospital or ambulatory electrocardiographic (ECG) monitoring, either continuous monitoring for 24 to 48 hours or longer-term patient activated event recording, is commonly obtained in the assessment of syncope. Such techniques are of limited diagnostic value because they are useful only if symptoms occur during monitoring, which is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/3,20,21\">",
"     3,20,21",
"    </a>",
"    ]. An asymptomatic arrhythmia does not prove an arrhythmic cause for syncope. Monitoring may be more helpful in excluding arrhythmia as the etiology of syncope if the patient has symptoms while monitored and no arrhythmia is recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2009 ESC syncope guidelines provided recommendations for ECG monitoring in patients with suspected arrhythmic syncope (",
"    <a class=\"graphic graphic_table graphicRef57636 \" href=\"UTD.htm?13/62/14317\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ECG monitoring is diagnostic when a correlation between syncope and an arrhythmia (brady or tachyarrhythmia) is detected.",
"     </li>",
"     <li>",
"      ECG monitoring excludes an arrhythmic cause when there is a correlation between syncope and lack of rhythm variation.",
"     </li>",
"     <li>",
"      In the absence of such correlations, ECG monitoring is considered diagnostic when there are ventricular pauses longer than 3 seconds or periods of Mobitz II or third degree atrioventricular block (with the possible exception of young trained individuals, during sleep, medicated patients, or rate-controlled atrial fibrillation), or rapid prolonged paroxysmal supraventricular or ventricular tachycardia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following are",
"    <strong>",
"     not",
"    </strong>",
"    accurate surrogates for syncope:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presyncope without any relevant arrhythmia.",
"     </li>",
"     <li>",
"      Asymptomatic arrhythmias (other than those listed above as diagnostic)",
"     </li>",
"     <li>",
"      Sinus bradycardia without syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     In-hospital monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;In-hospital monitoring is recommended in patients with structural heart disease who are deemed to be at high risk for life-threatening arrhythmias (",
"    <a class=\"graphic graphic_table graphicRef78397 \" href=\"UTD.htm?20/26/20908\">",
"     table 3",
"    </a>",
"    ). The expected diagnostic yield of such in-hospital monitoring is low (eg, 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/6\">",
"     6",
"    </a>",
"    ]) but justified by the potential risk of a life-threatening event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Continuous 24 to 48 hour (Holter) monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The value of 24 to 48 hour (short-term) continuous monitoring is limited due to the intermittent nature of syncope. In general, short-term continuous ambulatory monitoring appears to establish a diagnosis in only 1 to 3 percent of patients with syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, short-term monitoring may have some value in the selection of patients for invasive electrophysiology studies [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. In a series of 141 patients with unexplained syncope, the findings on ambulatory monitoring, in conjunction with other clinical predictors, identified patient subgroups that were more likely to have diagnostic abnormalities on electrophysiologic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'Electrophysiology study'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These considerations are reflected in the 2009 ESC syncope guidelines, which recommend Holter monitoring in patients who have clinical or ECG features suggesting an arrhythmic syncope such as those listed in the table (",
"    <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"     table 5",
"    </a>",
"    ) who have very frequent syncope or presyncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     External event recorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;External event recorders appear to be somewhat more helpful than short-term continuous ambulatory monitoring in diagnosing the etiology of syncope or presyncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/21\">",
"     21",
"    </a>",
"    ]. External event recorders can provide prospective",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    retrospective (loop) recordings. Prospective recorders often do not provide useful information because the patient must be conscious in order to activate the unit and record the rhythm at the time of the symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/26\">",
"     26",
"    </a>",
"    ]. Intermittent loop recorders may circumvent this difficulty if the unit has the ability to store several minutes of recording and if the patient activates the device immediately upon regaining consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/27\">",
"     27",
"    </a>",
"    ]. However, the reported diagnostic yield has been variable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/21,27,28\">",
"     21,27,28",
"    </a>",
"    ]. In one trial, despite patient education as part of the study, 23 percent of patients failed to activate their loop recorders properly at the time of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2009 ESC guidelines suggested that an external loop recorder may be indicated for patients who have clinical or ECG features, suggesting arrhythmic syncope such as those listed in the table (",
"    <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"     table 5",
"    </a>",
"    ) and an intersymptom interval of less than or equal to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Implantable loop recorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;The implantable loop recorder (ILR) is a subcutaneous monitoring device for the detection of cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/29\">",
"     29",
"    </a>",
"    ]. Such a device is typically implanted in the left parasternal or pectoral region and has a battery life of 18 to 24 months.",
"   </p>",
"   <p>",
"    The ILR stores recorded ECG strips when the device is activated according to programmed criteria (tachycardia or bradycardia thresholds), or when the patient manually activates it with magnet application. Retrospective recording permits capture of the rhythm during syncope by activation of the ILR after consciousness has returned. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link&amp;anchor=H8#H8\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\", section on 'Implantable loop recorder'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ILR may be most useful in patients with infrequent symptoms and a suspected arrhythmia in whom noninvasive testing is negative or inconclusive. In such patients, transient bradycardia is frequently found to be responsible, although symptoms associated with normal sinus rhythm (thus excluding an arrhythmic etiology), is also a common finding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/30-34\">",
"     30-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with neurocardiogenic syncope, an ILR may more accurately establish a causative relationship between bradyarrhythmias and syncope than provocative tests (eg, upright tilt table testing or electrophysiologic testing). However, it can be difficult to distinguish sinus node or AV node dysfunction from a neurocardiogenic response with ILR. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link&amp;anchor=H13#H13\">",
"     \"Reflex syncope\", section on 'Electrocardiographic monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An ILR may be used either in conjunction with or in preference to provocative tests. In syncope patients with a prior myocardial infarction or significant ECG abnormalities (eg, conduction abnormalities or evidence of a primary arrhythmia disorder), provocative testing is often appropriate in order to facilitate early diagnosis and treatment.",
"   </p>",
"   <p>",
"    In patients without prior myocardial infarction or significant ECG abnormalities, insertion of an ILR may be the preferred initial strategy for the evaluation of unexplained syncope as illustrated by the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/31,33-35\">",
"     31,33-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a small randomized trial, 60 patients (mean age of 66 years) were assigned to \"conventional\" testing with an external loop recorder and tilt and electrophysiological testing or to prolonged monitoring with an ILR with one year of monitoring [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/31\">",
"       31",
"      </a>",
"      ]. A diagnosis, most commonly bradycardia, was established more often with prolonged monitoring (55 versus 19 percent with conventional testing).",
"     </li>",
"     <li>",
"      The safety and efficacy of early ILR use were evaluated in a series of 392 patients with recurrent syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/34\">",
"       34",
"      </a>",
"      ]. Among 106 patients with a recurrent syncopal episode recorded on the ILR, 53 had therapy guided by this information (pacemakers in more than 80 percent), while the remaining patients had no specific therapy primarily because an arrhythmic cause was not identified. Recurrence rates were low among those with ILR-guided therapy (10 versus 41 percent among those who did not have an indication for and therefore did not receive ILR-guided therapy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risks associated with a prolonged ILR were not compared to provocative testing, but were relatively low. Seven patients (2 percent) suffered major trauma from syncope recurrence during ILR monitoring, and four patients (1 percent) developed ILR pocket infections. These risks should be balanced against the risks of early provocative testing; these include both false positive results, which may lead to unnecessary therapies, as well as false negative results, which delay diagnosis.",
"   </p>",
"   <p>",
"    Limited data suggests that use of an ILR is cost-effective compared to conventional approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H49\">",
"     'Cost for evaluation of syncope'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The 2009 ESC syncope guidelines include the following recommendations for use of ILRs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ILR is indicated for early phase evaluation in patients with recurrent syncope of uncertain origin, absence of high-risk criteria (",
"      <a class=\"graphic graphic_table graphicRef78397 \" href=\"UTD.htm?20/26/20908\">",
"       table 3",
"      </a>",
"      ), and a high likelihood of recurrence within the battery life of the device.",
"     </li>",
"     <li>",
"      An ILR is recommended in patients who have high-risk features (",
"      <a class=\"graphic graphic_table graphicRef78397 \" href=\"UTD.htm?20/26/20908\">",
"       table 3",
"      </a>",
"      ) in whom a comprehensive evaluation did not demonstrate a cause of syncope or lead to a specific treatment.",
"     </li>",
"     <li>",
"      An ILR should be considered to assess the contribution of bradycardia before embarking on cardiac pacing in patients with suspected or certain reflex syncope with frequent or traumatic syncopal episodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Electrophysiology study",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrophysiology study (EPS) is indicated in selected patients with unexplained syncope, particularly those with structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/24,36-40\">",
"     24,36-40",
"    </a>",
"    ]. Some patients with structural heart disease may have an indication for an implantable cardioverter-defibrillator and therefore may not necessarily require EP testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link&amp;anchor=H8#H8\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\", section on 'Syncope'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Indications for EPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the 2009 ESC syncope guidelines, EPS is recommended in the following clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef81195 \" href=\"UTD.htm?15/30/15853\">",
"     table 9",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with ischemic heart disease, EPS is recommended when initial evaluation suggests an arrhythmic cause of syncope (",
"      <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"       table 5",
"      </a>",
"      ) unless there is already an established indication for an implantable cardioverter-defibrillator (ICD). (See",
"      <a class=\"local\" href=\"#H44\">",
"       'ICD indications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients with bundle branch block, EPS should be considered when noninvasive tests have failed to make the diagnosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with structural heart disease or ECG abnormalities and unexplained syncope, 50 percent or more have a &ldquo;positive\" EP study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar recommendation for EPS in patients with structural heart disease (as well as consideration of EPS in patients with suspected arrhythmic cause) is included in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    ventricular arrhythmia and sudden death guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/40\">",
"     40",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    syncope guidelines recommend EPS in patients with coronary artery disease and syncope after an ischemia evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     EPS interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 ESC guidelines note that the following EPS findings are diagnostic (",
"    <a class=\"graphic graphic_table graphicRef81195 \" href=\"UTD.htm?15/30/15853\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus bradycardia and prolonged corrected sinus node recovery time (CSNRT) (&gt;525 ms)",
"     </li>",
"     <li>",
"      Bundle branch block and either a baseline His-ventricle (HV) interval of &ge;100 msec or second or third degree His-Purkinje block during incremental atrial pacing or pharmacologic challenge. An HV interval between 70 and 100 may be considered diagnostic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      One caveat in applying this criterion is that establishing a causal role of AV nodal dysfunction for syncope is difficult unless there is documented electrocardiographic evidence of high degree AV block. Conduction system abnormalities often occur in patients with underlying heart disease in whom the potential substrate for ventricular tachyarrhythmias also frequently exists. In such patients, a ventricular arrhythmia must be excluded scrupulously as a possible underlying cause for syncope before establishing bradycardia as the etiology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Induction of sustained monomorphic ventricular tachycardia in patients with prior myocardial infarction",
"     </li>",
"     <li>",
"      Induction of rapid supraventricular tachycardia which reproduces hypotensive or spontaneous symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By comparison, the induction of nonsustained ventricular tachycardia, polymorphic ventricular tachycardia, and ventricular fibrillation is less helpful as these findings may be nonspecific.",
"   </p>",
"   <p>",
"    Syncope associated with ventricular tachycardia induced during an EP study indicates a high risk for death. In one study, for example, the one and four year all-cause and sudden death mortalities were equivalent to those of patients with documented spontaneous ventricular tachycardia (with or without syncope) or ventricular fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     ICD indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In certain patient populations, implantable cardioverter-defibrillator (ICD) therapy may be indicated regardless of EPS results. Thus, EPS is not necessary in such patients unless warranted to establish a specific diagnosis.",
"   </p>",
"   <p>",
"    Patients with LVEF &le;30 percent and prior history of myocardial infarction (with or without history of syncope) are appropriate candidates for ICD therapy, regardless of EPS results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H29#H29\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'ICD therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ischemic or nonischemic heart disease with LVEF &le;35 percent with NYHA class II to III heart failure (and some with class IV heart failure) are appropriate candidates for ICD therapy, regardless of EPS results. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link&amp;anchor=H28#H28\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\", section on 'Primary prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382534\">",
"    <span class=\"h2\">",
"     Exercise testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although exercise testing generally has a low diagnostic yield in patients with syncope (less than 1 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/3\">",
"     3",
"    </a>",
"    ], it may be helpful in patients with specific indications.",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    guidelines recommended exercise testing in syncope patients at risk for or with a history of coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/4\">",
"     4",
"    </a>",
"    ], while the 2009 ESC guidelines recommended exercise testing in patients with syncope during or shortly after exertion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]. Echocardiography is recommended prior to exercise testing.",
"   </p>",
"   <p>",
"    Exercise testing is diagnostic when the following findings occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syncope is reproduced during or immediately after exercise in the presence of ECG abnormalities or severe hypotension.",
"     </li>",
"     <li>",
"      Mobitz II second degree or third degree AV block develops during exercise even without syncope. This response suggests block distal to the AV node and is predictive of progression to permanent AV block. Patients with this response frequently have resting intraventricular conduction abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Syncope during exercise occurs in patients with or without cardiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syncope during exercise in patients with ischemic heart disease may be caused by either low output (with or without arrhythmia) or the Bezold-Jarisch reflex. Hypotension during exercise in patients less than 40 years of age suggests possible left main coronary artery disease or hypertrophic cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy\", section on 'Exercise testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Reflex syncope during exercise occurs with marked hypotension without bradycardia.",
"     </li>",
"     <li>",
"      In elderly patients, hypotension during exercise may be due to autonomic failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Postexertional syncope may be associated with marked bradycardia or asystole and is generally due to a neurally-mediated mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Exercise testing may also be helpful in other settings. Failure to shorten the QT interval with exercise may be a sign of congenital long QT syndrome even when this abnormality is not apparent in the resting electrocardiogram. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link\">",
"     \"Diagnosis of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1382541\">",
"    <span class=\"h2\">",
"     Brain natriuretic peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brain natriuretic peptide (BNP) is a natriuretic hormone that is released from myocardial cells in response to volume expansion and possibly increased cardiac wall stress. Elevated plasma BNP concentrations are typically seen in patients with heart failure and may be seen in a variety of other cardiovascular disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that measurement of plasma BNP may be useful in distinguishing cardiac from noncardiac causes of syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/43\">",
"     43",
"    </a>",
"    ]. Such testing was not discussed in the 2009 ESC syncope guidelines or the 2006",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    syncope guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After these guidelines were published, a prospective, observational study suggested that an elevated BNP level may have value either as an isolated predictor of adverse events or as a component of a clinical decision rule in patients presenting with syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/44\">",
"     44",
"    </a>",
"    ]. The ROSE (Risk stratification Of Syncope in the Emergency department) rule was developed from data on adverse outcomes at one month in 550 patients presenting to an emergency department with syncope. The rule was tested in a validation cohort of another 550 patients.",
"   </p>",
"   <p>",
"    The ROSE rule recommends hospital admission if any of the following independent predictors of adverse outcome is present (mnemonic is BRACES):",
"    <strong>",
"     B",
"    </strong>",
"    NP level &ge;300",
"    <span class=\"nowrap\">",
"     pg/ml,",
"    </span>",
"    bradycardia &le;50 bpm in the emergency department or prehospital,",
"    <strong>",
"     r",
"    </strong>",
"    ectal examination showing fecal occult blood (examination performed if suspicion of gastrointestinal bleed),",
"    <strong>",
"     a",
"    </strong>",
"    nemia with hemoglobin &le;9",
"    <span class=\"nowrap\">",
"     g/dl,",
"    </span>",
"    <strong>",
"     c",
"    </strong>",
"    hest pain associated with syncope,",
"    <strong>",
"     E",
"    </strong>",
"    CG showing Q wave (not in lead III) or oxygen",
"    <strong>",
"     s",
"    </strong>",
"    aturation &le;94 percent on room air.",
"   </p>",
"   <p>",
"    At one month, serious outcome or all-cause death occurred in 7 percent of the derivation cohort and validation cohorts. In the validation cohort, the ROSE rule had a sensitivity and specificity for adverse events at one month of 87 and 66 percent, and a negative predictive value of 98.5 percent. An elevated BNP level alone was a predictor of serious cardiovascular outcomes (8 of 22 events) and all-cause deaths (8 of 9 deaths). Additional validation is required to determine the value of this clinical prediction rule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Adenosine and adenosine triphosphate (ATP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine or the related precursor compound adenosine triphosphate (ATP) provoke a short and potent cardioinhibitory response of vagal origin. The administration of these drugs can produce a variety of responses, including sinus bradycardia or pauses, atrioventricular (AV) block, and vasodepression.",
"   </p>",
"   <p>",
"    Although ATP testing was previously suggested, the 2009 ESC syncope guidelines note that there is a lack of correlation between spontaneous syncope and ATP results so this test is not helpful to select patients for cardiac pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Cardiac catheterization and coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in the 2009 ESC syncope guidelines, angiography alone is rarely diagnostic of the cause of syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in patients with syncope suspected to be directly or indirectly due to myocardial ischemia, coronary angiography is recommended to confirm the diagnosis and to establish optimal therapy.",
"   </p>",
"   <p>",
"    If an anomalous coronary artery origin is suspected (as syncope may be exercise induced and associated with chest discomfort in a patient at otherwise low risk for coronary disease), evaluation by transesophageal echocardiography (or transthoracic echocardiography if acoustic windows allow), cardiovascular magnetic resonance, or computed tomography enables identification of the coronary origins, so invasive coronary angiography is generally not required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=see_link\">",
"     \"Congenital and pediatric coronary artery abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Signal-averaged electrocardiogram and T-wave alternans",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     AHA/ACC",
"    </span>",
"    scientific statement on syncope indicated that routine use of T-wave alternans with signal-averaged ECG and assessment of heart rate variability in patients with syncope and a negative initial evaluation is not established and currently is not indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24089227\">",
"    <span class=\"h2\">",
"     Psychiatric evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2009 ESC guidelines recommended psychiatric evaluation when symptoms suggest psychogenic pseudosyncope or if true syncope is due to psychiatric medications that may need to be altered [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=see_link\">",
"     \"Psychogenic nonepileptic seizures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24089318\">",
"    <span class=\"h2\">",
"     Neurologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic disorders may cause syncope as a result of autonomic failure or cerebrovascular disorders (primarily via steal syndromes) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]. Other neurologic disorders can cause transient loss of consciousness that may be confused with syncope (",
"    <a class=\"graphic graphic_table graphicRef76023 \" href=\"UTD.htm?23/58/24491\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Neurologic tests, including electroencephalogram (EEG), brain CT scan, brain magnetic resonance imaging, and carotid Doppler ultrasound, are frequently obtained in patients with syncope. In one review of 649 patients, 53 percent had at least one neurologic test [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/18\">",
"     18",
"    </a>",
"    ]. However, such testing was rarely useful.",
"   </p>",
"   <p>",
"    An EEG may help diagnose epilepsy in patients who have episodes of loss of consciousness with seizure-like activity, although an interictal epileptiform discharge is found in only 20 to 55 percent of persons with epilepsy on a first routine EEG. The sensitivity of electroencephalography can be increased by repeated testing. However, some seizure-like attacks have a cardiovascular cause identifiable by noninvasive cardiac testing [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Distinction of syncope from seizures'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=see_link\">",
"     \"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2009 ESC guidelines recommended neurologic referral in patients in whom transient loss of consciousness is suspected to be epilepsy rather than syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, neurologic referral to evaluate the underlying disease is indicated when syncope is due to autonomic failure. An EEG or carotid Doppler ultrasound study, computed tomography or magnetic resonance imaging is not recommended unless a non-syncopal cause of transient loss of consciousness is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     EVALUATION OF ELDERLY ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of syncope in the elderly are orthostatic hypotension, reflex syncope (particularly carotid sinus syndrome), and cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]. Diagnosis may be complicated by the presence of multiple types of syncope in a patient. Distinguishing falls from syncope may be difficult. History taking should include witness observations when available and medication details. Syncope occurring in the morning is suggestive of orthostatic hypotension (OH).",
"   </p>",
"   <p>",
"    Particular considerations in the elderly include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of OH is not always reproducible so repeat evaluation of orthostatic BP may be necessary, particularly in the morning",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      promptly after syncope.",
"     </li>",
"     <li>",
"      The evaluation of mobile, independent, cognitively intact older adults is as for younger patients except that routine supine and upright carotid sinus massage is suggested (unless there are contraindications) in the 2009 ESC guidelines [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"       1",
"      </a>",
"      ]. Carotid sinus hypersensitivity is frequent in older adults even when history is nonspecific.",
"     </li>",
"     <li>",
"      Tilt testing is well tolerated and safe in older adults.",
"     </li>",
"     <li>",
"      Twenty-four hour ambulatory BP recordings can be helpful if intermittent hypotension is suspected (eg, due to medication or post-prandial).",
"     </li>",
"     <li>",
"      Since arrhythmias are frequent in elderly adults, an ILR may be particularly helpful in elderly adults with unexplained syncope.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1380879\">",
"    <span class=\"h2\">",
"     Evaluation of the frail elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;For frail older adults, the evaluation should be modified according to prognosis and expectation of benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     COST FOR EVALUATION OF SYNCOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing in patients with syncope is costly; the cost per diagnosis obtained ranges from $529 with an external loop recorder to $73,260 for an electrophysiologic study in patients without structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/35\">",
"     35",
"    </a>",
"    ]. The use of an implantable loop recorder can reduce the cost of investigating syncope. In one series of 24 patients with recurrent syncope of uncertain origin, a diagnosis was established with an implantable recorder in 88 percent; the cost of investigation was much lower after the use of the implantable recorder than before ($2452 versus $7584) (",
"    <a class=\"graphic graphic_table graphicRef75665 \" href=\"UTD.htm?35/18/36139\">",
"     table 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second study evaluated 7959 patients over 65 years of age who were admitted to the hospital with a diagnosis of syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/46\">",
"     46",
"    </a>",
"    ]. The average annual cost for inpatient admissions, outpatient procedures, and physician visits was $4132 (in 1993 dollars); the average annual cost for patients with recurrent syncope of unknown origin was $5281 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syncope should be differentiated from other types of real or apparent transient loss of consciousness. Identification of the underlying etiology for syncope can often be made from the history, physical examination, and an electrocardiogram. (See",
"      <a class=\"local\" href=\"#H14005354\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical features of a syncopal event are important and may be diagnostic (",
"      <a class=\"graphic graphic_table graphicRef55096 \" href=\"UTD.htm?29/30/30188\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"       table 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If syncope occurs with exertion, evaluation should include assessment for potentially life-threatening causes (such aortic stenosis or hypertrophic cardiomyopathy). (See",
"      <a class=\"local\" href=\"#H1381002\">",
"       'Exertional syncope'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injury from syncope does not predict the cause for syncope. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Seizures may be difficult to differentiate from syncopal episodes. Some seizures may not be associated with tonic-clonic movements and some patients with syncope have myoclonic movements suggestive of a seizure disorder that are actually due to cerebral hypoxia. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Distinction of syncope from seizures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the diagnosis is uncertain following the initial evaluation, further evaluation and management should be guided by risk stratification [",
"      <a class=\"abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"       1",
"      </a>",
"      ] (See",
"      <a class=\"local\" href=\"#H16427095\">",
"       'Risk stratification'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If clinical features of high risk of short-term serious event are present (",
"      <a class=\"graphic graphic_table graphicRef78397 \" href=\"UTD.htm?20/26/20908\">",
"       table 3",
"      </a>",
"      ), early evaluation and treatment are indicated. Short-term, high-risk criteria indicate need for intensive evaluation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prompt hospitalization.",
"     </li>",
"     <li>",
"      If there are single or rare episodes of syncope with low-risk clinical features, no further evaluation is indicated. Such patients probably have reflex syncope and tests for confirmation are usually not necessary.",
"     </li>",
"     <li>",
"      If there are recurrent episodes with low-risk features, work-up should include tests for cardiac or neurally-mediated causes, as appropriate (",
"      <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"       table 5",
"      </a>",
"      ). Treatment may be deferred and should be guided by the results of ECG documentation and other tests. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional testing is based on the results of the initial evaluation (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Testing'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Carotid sinus massage in patients &gt;40 years old. (See",
"      <a class=\"local\" href=\"#H1939404\">",
"       'Carotid sinus massage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiogram when there is previous known heart disease or data suggestive of structural heart disease or syncope secondary to cardiovascular cause (",
"      <a class=\"graphic graphic_table graphicRef66884 \" href=\"UTD.htm?5/51/5949\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate ECG monitoring when there is a suspicion of arrhythmic syncope (",
"      <a class=\"graphic graphic_table graphicRef78397 \" href=\"UTD.htm?20/26/20908\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Electrocardiographic monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Orthostatic challenge (lying to standing orthostatic test or head-up tilt testing) when syncope is related to the standing position or there is suspicion of a reflex mechanism. (See",
"      <a class=\"local\" href=\"#H1939581\">",
"       'Orthostatic challenge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other less specific tests such as neurologic evaluation or blood tests are indicated only when there is suspicion of nonsyncopal transient loss of consciousness. (See",
"      <a class=\"local\" href=\"#H24089318\">",
"       'Neurologic testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients without heart disease, evaluation for reflex syncope should be considered for those with recurrent or severe unexplained syncope. Tests for reflex syncope include carotid massage and possibly tilt testing; if these are negative, prolonged ECG monitoring may be helpful. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Electrocardiographic monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/1\">",
"      Task Force for the Diagnosis and Management of Syncope, European Society of Cardiology (ESC), European Heart Rhythm Association (EHRA), et al. Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J 2009; 30:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/2\">",
"      Alboni P, Brignole M, Menozzi C, et al. Diagnostic value of history in patients with syncope with or without heart disease. J Am Coll Cardiol 2001; 37:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/3\">",
"      Kapoor WN. Evaluation and outcome of patients with syncope. Medicine (Baltimore) 1990; 69:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/4\">",
"      Strickberger SA, Benson DW, Biaggioni I, et al. AHA/ACCF Scientific Statement on the evaluation of syncope: from the American Heart Association Councils on Clinical Cardiology, Cardiovascular Nursing, Cardiovascular Disease in the Young, and Stroke, and the Quality of Care and Outcomes Research Interdisciplinary Working Group; and the American College of Cardiology Foundation: in collaboration with the Heart Rhythm Society: endorsed by the American Autonomic Society. Circulation 2006; 113:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/5\">",
"      Sarasin FP, Louis-Simonet M, Carballo D, et al. Prospective evaluation of patients with syncope: a population-based study. Am J Med 2001; 111:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/6\">",
"      Crane SD. Risk stratification of patients with syncope in an accident and emergency department. Emerg Med J 2002; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/7\">",
"      Croci F, Brignole M, Alboni P, et al. The application of a standardized strategy of evaluation in patients with syncope referred to three syncope units. Europace 2002; 4:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/8\">",
"      Linzer M, Yang EH, Estes NA 3rd, et al. Diagnosing syncope. Part 1: Value of history, physical examination, and electrocardiography. Clinical Efficacy Assessment Project of the American College of Physicians. Ann Intern Med 1997; 126:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/9\">",
"      Calkins H, Shyr Y, Frumin H, et al. The value of the clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block, and neurocardiogenic syncope. Am J Med 1995; 98:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/10\">",
"      Grimm W, Degenhardt M, Hoffman J, et al. Syncope recurrence can better be predicted by history than by head-up tilt testing in untreated patients with suspected neurally mediated syncope. Eur Heart J 1997; 18:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/11\">",
"      Del Rosso A, Ungar A, Maggi R, et al. Clinical predictors of cardiac syncope at initial evaluation in patients referred urgently to a general hospital: the EGSYS score. Heart 2008; 94:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/12\">",
"      Krahn AD, Klein GJ, Yee R, et al. Predictive value of presyncope in patients monitored for assessment of syncope. Am Heart J 2001; 141:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/13\">",
"      Sakaguchi S, Shultz JJ, Remole SC, et al. Syncope associated with exercise, a manifestation of neurally mediated syncope. Am J Cardiol 1995; 75:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/14\">",
"      Colivicchi F, Ammirati F, Biffi A, et al. Exercise-related syncope in young competitive athletes without evidence of structural heart disease. Clinical presentation and long-term outcome. Eur Heart J 2002; 23:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/15\">",
"      WAYNE HH. Syncope. Physiological considerations and an analysis of the clinical characteristics in 510 patients. Am J Med 1961; 30:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/16\">",
"      Sheldon R, Rose S, Ritchie D, et al. Historical criteria that distinguish syncope from seizures. J Am Coll Cardiol 2002; 40:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/17\">",
"      Passman R, Horvath G, Thomas J, et al. Clinical spectrum and prevalence of neurologic events provoked by tilt table testing. Arch Intern Med 2003; 163:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/18\">",
"      Pires LA, Ganji JR, Jarandila R, Steele R. Diagnostic patterns and temporal trends in the evaluation of adult patients hospitalized with syncope. Arch Intern Med 2001; 161:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/19\">",
"      Sarasin FP, Junod AF, Carballo D, et al. Role of echocardiography in the evaluation of syncope: a prospective study. Heart 2002; 88:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/20\">",
"      Gibson TC, Heitzman MR. Diagnostic efficacy of 24-hour electrocardiographic monitoring for syncope. Am J Cardiol 1984; 53:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/21\">",
"      Sivakumaran S, Krahn AD, Klein GJ, et al. A prospective randomized comparison of loop recorders versus Holter monitors in patients with syncope or presyncope. Am J Med 2003; 115:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/22\">",
"      Clark PI, Glasser SP, Spoto E Jr. Arrhythmias detected by ambulatory monitoring. Lack of correlation with symptoms of dizziness and syncope. Chest 1980; 77:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/23\">",
"      Kapoor WN, Cha R, Peterson JR, et al. Prolonged electrocardiographic monitoring in patients with syncope. Importance of frequent or repetitive ventricular ectopy. Am J Med 1987; 82:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/24\">",
"      Bachinsky WB, Linzer M, Weld L, Estes NA 3rd. Usefulness of clinical characteristics in predicting the outcome of electrophysiologic studies in unexplained syncope. Am J Cardiol 1992; 69:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/25\">",
"      Linzer M, Prystowsky EN, Divine GW, et al. Predicting the outcomes of electrophysiologic studies of patients with unexplained syncope: preliminary validation of a derived model. J Gen Intern Med 1991; 6:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/26\">",
"      Zimetbaum PJ, Josephson ME. The evolving role of ambulatory arrhythmia monitoring in general clinical practice. Ann Intern Med 1999; 130:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/27\">",
"      Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. Am J Cardiol 1990; 66:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/28\">",
"      Schuchert A, Maas R, Kretzschmar C, et al. Diagnostic yield of external electrocardiographic loop recorders in patients with recurrent syncope and negative tilt table test. Pacing Clin Electrophysiol 2003; 26:1837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/29\">",
"      Krahn AD, Klein GJ, Skanes AC, Yee R. Insertable loop recorder use for detection of intermittent arrhythmias. Pacing Clin Electrophysiol 2004; 27:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/30\">",
"      Krahn AD, Klein GJ, Fitzpatrick A, et al. Predicting the outcome of patients with unexplained syncope undergoing prolonged monitoring. Pacing Clin Electrophysiol 2002; 25:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/31\">",
"      Krahn AD, Klein GJ, Yee R, Skanes AC. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy. Circulation 2001; 104:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/32\">",
"      Krahn AD, Klein GJ, Yee R, et al. Use of an extended monitoring strategy in patients with problematic syncope. Reveal Investigators. Circulation 1999; 99:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/33\">",
"      Farwell DJ, Freemantle N, Sulke AN. Use of implantable loop recorders in the diagnosis and management of syncope. Eur Heart J 2004; 25:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/34\">",
"      Brignole M, Sutton R, Menozzi C, et al. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope. Eur Heart J 2006; 27:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/35\">",
"      Krahn AD, Klein GJ, Yee R, Manda V. The high cost of syncope: cost implications of a new insertable loop recorder in the investigation of recurrent syncope. Am Heart J 1999; 137:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/36\">",
"      Olshansky B, Mazuz M, Martins JB. Significance of inducible tachycardia in patients with syncope of unknown origin: a long-term follow-up. J Am Coll Cardiol 1985; 5:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/37\">",
"      Kapoor WN, Hammill SC, Gersh BJ. Diagnosis and natural history of syncope and the role of invasive electrophysiologic testing. Am J Cardiol 1989; 63:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/38\">",
"      Teichman SL, Felder SD, Matos JA, et al. The value of electrophysiologic studies in syncope of undetermined origin: report of 150 cases. Am Heart J 1985; 110:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/39\">",
"      Krol RB, Morady F, Flaker GC, et al. Electrophysiologic testing in patients with unexplained syncope: clinical and noninvasive predictors of outcome. J Am Coll Cardiol 1987; 10:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/40\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/41\">",
"      Linzer M, Yang EH, Estes NA 3rd, et al. Diagnosing syncope. Part 2: Unexplained syncope. Clinical Efficacy Assessment Project of the American College of Physicians. Ann Intern Med 1997; 127:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/42\">",
"      Olshansky B, Hahn EA, Hartz VL, et al. Clinical significance of syncope in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. The ESVEM Investigators. Am Heart J 1999; 137:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/43\">",
"      Tanimoto K, Yukiiri K, Mizushige K, et al. Usefulness of brain natriuretic peptide as a marker for separating cardiac and noncardiac causes of syncope. Am J Cardiol 2004; 93:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/44\">",
"      Reed MJ, Newby DE, Coull AJ, et al. The ROSE (risk stratification of syncope in the emergency department) study. J Am Coll Cardiol 2010; 55:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/45\">",
"      Zaidi A, Clough P, Cooper P, et al. Misdiagnosis of epilepsy: many seizure-like attacks have a cardiovascular cause. J Am Coll Cardiol 2000; 36:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/15/18682/abstract/46\">",
"      Nyman JA, Krahn AD, Bland PC, et al. The costs of recurrent syncope of unknown origin in elderly patients. Pacing Clin Electrophysiol 1999; 22:1386.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 969 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-D3C9B8B2AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18682=[""].join("\n");
var outline_f18_15_18682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H50\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14005354\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16427295\">",
"      - Type of episode",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Number of episodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Associated symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Prodrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Sudden onset",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Position",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16427389\">",
"      - Provocative factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1381002\">",
"      - Exertional syncope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Duration of symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Witnessed signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Preexisting medical conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1939366\">",
"      - Family history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Medications or recreational drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Distinction of syncope from seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Abnormal vital signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Disturbances in heart rhythm or breathing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cardiac auscultatory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Physiologic maneuvers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Abnormal neurologic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Gastrointestinal bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16427095\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1939404\">",
"      Carotid sinus massage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1939581\">",
"      Orthostatic challenge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1939497\">",
"      - Active standing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1939518\">",
"      - Tilt testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1380566\">",
"      Orthostatic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Electrocardiographic monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - In-hospital monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Continuous 24 to 48 hour (Holter) monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - External event recorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Implantable loop recorder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Electrophysiology study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Indications for EPS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - EPS interpretation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - ICD indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1382534\">",
"      Exercise testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1382541\">",
"      Brain natriuretic peptide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Adenosine and adenosine triphosphate (ATP)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Cardiac catheterization and coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Signal-averaged electrocardiogram and T-wave alternans",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24089227\">",
"      Psychiatric evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24089318\">",
"      Neurologic testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      EVALUATION OF ELDERLY ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1380879\">",
"      Evaluation of the frail elderly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      COST FOR EVALUATION OF SYNCOPE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/969\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/969|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/31/8701\" title=\"table 1\">",
"      Classification of syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/58/24491\" title=\"table 2\">",
"      Conditions incorrectly diagnosed as syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/26/20908\" title=\"table 3\">",
"      Risk stratification for syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/30/30188\" title=\"table 4\">",
"      Diagnostic criteria for syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/51/5949\" title=\"table 5\">",
"      Clinical features that suggest a diagnosis on intial evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/6/36973\" title=\"table 6\">",
"      Seizures versus syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/25/35227\" title=\"table 7\">",
"      ESC recommendations carotid sinus massage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/62/14317\" title=\"table 8\">",
"      Electrocardiographic monitoring for syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/30/15853\" title=\"table 9\">",
"      Electrophysiological study for syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/18/36139\" title=\"table 10\">",
"      Test cost and diagnostic yield",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23223?source=related_link\">",
"      Approach to the patient with dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23192?source=related_link\">",
"      Arrhythmia in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=related_link\">",
"      Carotid sinus hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36522?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14218?source=related_link\">",
"      Congenital and pediatric coronary artery abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32425?source=related_link\">",
"      Electroencephalography (EEG) in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28855?source=related_link\">",
"      Management of the patient with syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/41/18074?source=related_link\">",
"      Nonepileptic paroxysmal disorders in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=related_link\">",
"      Pathogenesis and etiology of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41876?source=related_link\">",
"      Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29159?source=related_link\">",
"      Postural tachycardia syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33226?source=related_link\">",
"      Psychogenic nonepileptic seizures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27399?source=related_link\">",
"      Upright tilt table testing in the evaluation of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=related_link\">",
"      Vagal maneuvers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_15_18683="Dix Hallpike findings in central vs peripheral vertigo";
var content_f18_15_18683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dix-Hallpike maneuver for positional nystagmus: findings in central versus peripheral vertigo",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Peripheral disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Central disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Latent period before onset of positional nystagmus",
"       </td>",
"       <td>",
"        2 to 20 seconds",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duration of nystagmus",
"       </td>",
"       <td>",
"        Less than 1 minute",
"       </td>",
"       <td>",
"        Greater than 1 minute",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatiguability",
"       </td>",
"       <td>",
"        Fatiguing with repetition",
"       </td>",
"       <td>",
"        Nonfatiguing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Direction of nystagmus",
"       </td>",
"       <td>",
"        Only one type, may change direction with gaze",
"       </td>",
"       <td>",
"        May change direction with a given head position",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intensity of vertigo",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        Less severe, sometimes none",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18683=[""].join("\n");
var outline_f18_15_18683=null;
var title_f18_15_18684="The localization of abducens nerve lesions";
var content_f18_15_18684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55159&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The localization of abducens nerve lesions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Structure involved",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical presentation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Nuclear lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Abducens nucleus",
"       </td>",
"       <td>",
"        Horizontal gaze palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        M&ouml;bius syndrome (gaze palsy with facial diplegia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Duane retraction syndrome (gaze palsy with globe retraction and narrowing of palpebral fissure with adduction)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dorsolateral pons",
"       </td>",
"       <td>",
"        Foville syndrome (ipsilateral gaze palsy, facial paresis, dysmetria occasionally with contralateral hemiparesis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Lesions of the abducens fascicle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abducens fascicle",
"       </td>",
"       <td>",
"        Isolated CN VI palsy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anterior paramedial pons",
"       </td>",
"       <td>",
"        Ipsilateral CN VI palsy, ipsilateral CN VII palsy, contralateral hemiparesis (Millard-Gubler)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prepontine cistern",
"       </td>",
"       <td>",
"        May have contralateral hemiparesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Lesion of abducens nerve (subarachnoid, petrous)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Petrous apex (Dorello canal)",
"       </td>",
"       <td>",
"        CN VI palsy, deafness, facial (especially retroorbital) pain (Gradenigo)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cavernous sinus",
"        </strong>",
"       </td>",
"       <td>",
"        Isolated CN VI palsy; CN VI palsy plus Horner syndrome; also may affect CN III, IV, V1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Superior orbital fissure syndrome",
"        </strong>",
"       </td>",
"       <td>",
"        CN VI palsy with varible affection of CN III, IV, V1; proptosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Orbit",
"        </strong>",
"       </td>",
"       <td>",
"        CN VI palsy; visual loss; variable proptosis, chemosis, lid swelling",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Brazis PW, Masdeu JC, Biller J. Localization in Clinical Neurology, Fourth Edition. Lippincott Williams &amp; Wilkins, 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18684=[""].join("\n");
var outline_f18_15_18684=null;
var title_f18_15_18685="Difficulty replicating";
var content_f18_15_18685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Reasons for inability to replicate genetic associations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Possible reasons",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        True variation in the underlying association between genotype and outcome between populations studied",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Disease-causing allele is in linkage disequilibrium (ie, is associated) with a different allele at the marker locus (ie, the locus under study) in different groups",
"       </td>",
"       <td>",
"        Unlikely that allelic associations will vary much between continental populations, apart from when disease-causing variant is rare or has been subject to differential selection pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Allelic heterogeneity exists between ethnic groups: different variants within the same gene contribute to disease risk",
"       </td>",
"       <td>",
"        Unlikely that much allelic heterogeneity will be present within continental populations, apart from when disease-causing variant is rare or has been subject to differential selection pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        The association is modified by other genetic or environmental factors that vary between the groups studied",
"       </td>",
"       <td>",
"        Effect modification by genes unlikely to account for failure to replicate studies in similar populations. Modification by environmental factors more likely, not especially when absolute risk of disease varies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Biases vary between studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Selection bias: population at risk consists of strata that vary by allele frequencies at the marker locus, or the population is admixed, and the probability of being selected as a case or control varies by stratum",
"       </td>",
"       <td>",
"        Avoidable by careful sampling strategy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Differential misclassification of exposure: for instance, when cases and controls have been genotyped in separate batches with genotyping error rates that vary between batches",
"       </td>",
"       <td>",
"        Easily avoided by appropriate laboratory procedures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Differential misclassification of outcome: possible if genotype is known when outcome is classified",
"       </td>",
"       <td>",
"        Unlikely, because outcome is usually defined in advance of genotyping",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Confounding by population substructure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Population is divided into strata that vary by disease risk and by allele frequencies at the marker locus",
"       </td>",
"       <td>",
"        Unlikely to be a serious problem in most studies: when confounding is a problem, it can be controlled in study design by restriction or use of family-based controls, or in the analysis by quantifying and controlling for substructure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Absence of power leading to false-negative results in studies that do not replicate earlier positive findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inadequate sample sizes, or differences in the efficiency of the sampling strategy (for instance sampling the entire distribution of a trait, instead of the tails of the distribution)",
"       </td>",
"       <td>",
"        Need to establish whether a negative study had adequate power to detect an association of the size originally reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Non-differential misclassification of outcome",
"       </td>",
"       <td>",
"        Even substantial misclassification of outcome can be compensated for by modest increases in sample size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Failure to consider that the initial effect size reported is an inflation of the true effect size",
"       </td>",
"       <td>",
"        Replication studies should be powered to detect effect sizes that are smaller than the initial effect size reported, especially when the initial study had low power",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Case mix heterogeneity in an apparently homogenous outcome between populations studied: for instance in a study of stroke, mix of haemorrhagic and thrombotic subtypes may vary between populations",
"       </td>",
"       <td>",
"        Unlikely to be an explanation for failure to replicate studies in similar populations with similar case sampling strategies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        False positive results by chance in initial positive studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple testing and publication bias: multiple loci are assessed in each study, many statistical tests are done, and multiple studies are undertaken but only positive results are reported",
"       </td>",
"       <td>",
"        The most likely reason for failure to replicate",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Colhoun HM, McKeigue PM, Smith GD. Problems of reporting genetic associations with complex outcomes. Lancet 2003; 361:865. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18685=[""].join("\n");
var outline_f18_15_18685=null;
var title_f18_15_18686="TEE aortic plaque";
var content_f18_15_18686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/76326/teeaopla_conv.mp4?title=TEE+aortic+plaque\" style=\"width:383px;height:276px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic plaque",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 225px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram show a large, mobile aortic plaque (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18686=[""].join("\n");
var outline_f18_15_18686=null;
var title_f18_15_18687="Effect of Anti-IgE";
var content_f18_15_18687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72697&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Efficacy of anti-IgE therapy in asthma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 479px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Results of United States phase III study showing that symptom control is maintained with omalizumab during the steroid-withdrawal phase. Mean change from baseline in total asthma symptom scores and the number of puffs of rescue medication (albuterol) per day.",
"    <div class=\"footnotes\">",
"     * p &lt;0.05.",
"     <br>",
"      ** p&lt;0.01.",
"      <br>",
"       *** p&lt;0.001.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Busse, WJ. Anti-immunoglobulin E (Omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med 2001; 164:S12. Copyright &copy; 2001 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_15_18687=[""].join("\n");
var outline_f18_15_18687=null;
